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Chapter 1
INTRODUCTION
Polycystic liver disease
Polycystic liver diseases (PLD) are a group of genetic disorders characterized by the progressive 
formation of hepatic cysts. 1 PLD is present in two genetically distinct disorders; as the primary 
phenotype in autosomal dominant PLD (ADPLD); and secondary to renal cysts in autosomal 
dominant polycystic kidney disease (ADPKD). In this thesis I focus on the phenotype and 
treatment of PLD in both disorders. 
ADPLD is a rare disease and a prevalence of 1: 158.000 has been estimated in the Netherlands.2 
Mutations in PRKCSH, Sec63 or LRP5 are associated with ADPLD, though collectively they only 
account for approximately 25% of the cases.
ADPKD is the most common inherited renal disease (prevalence of 1:400-1:1000) and is 
characterized by the development of renal cysts and a variety of extra-renal manifestations.3 
Progressive kidney cyst growth leads to end-stage renal disease in a large proportion of 
patients, typically after the fourth decade of life. 3-5 Liver cysts are the most common extra-
renal phenotype in ADPKD, present in 94% of the population older than 35 years. 6 In contrast 
to ADPLD, almost 100% of cases can be explained by mutations in known genes. PKD1 or PKD2 
mutations are identified in respectively 80-85% and 15-20% of the ADPKD population. 4 
Pathophysiology
Several signal transduction pathways are activated in polycystic livers regulating cyst growth. 
The PKD genes involved in this process encode for polycystin 1 and 2. These are integral 
membrane proteins acting as a Ca2+ permeable receptor channel complex. Mutations in 
polycystins result in decreased intracellular Ca2+ levels and subsequent increased intracellular 
cyclic adenosine monophosphate (cAMP) levels. This leads to cholangiocyte hyperproliferation, 
enhanced fluid secretion and eventually progressive cyst formation and growth. 1,7 
Diagnosis 
Diagnosis of PLD can be made by radiological imaging such as ultrasonography, CT or MRI 
scan.1 There is no strict definition for PLD. A cut-off value of ≥ 20 liver cysts is often used 
in literature because we assume that the presence of ≥ 20 cysts is due to ADPLD or ADPKD, 
instead of sporadic cysts. 
For the diagnosis of ADPKD in individuals with a known family history of ADPKD, diagnosis is 
based on modified Ravine criteria which includes age and number of cysts. 8 In absence of a 
family history of ADPKD, a presumptive diagnosis can be made when >10 cysts in each kidney 
are present and other renal diseases are absent. 9
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
9
General introduction and outline
1
Both ADPLD and ADPKD can be confirmed by genetic testing. As indicated, only a minority of 
ADPLD patients have a genetic mutation. Hence, genetic testing is not part of clinical practice 
because of technical challenges and high costs of DNA analysis. Therefore, diagnostic testing is 
restricted to cases with equivocal or atypical renal imaging findings.5 
Disease severity
Liver phenotype, in terms of number, size and spread of cysts throughout the liver is an 
important indicator used to determine treatment strategy. Classification of liver phenotype 
by Gigot, Schnelldorfer or Qian’s categorization might help to choose the right treatment 
strategy for individual patients. 10-12 However, categorization of patients according to these 
classifications is not standard of care.
A normal liver weighs approximately 1500mL. 13 Presence of PLD can drive liver volume to 
>10L in some patients. 1 Disease severity can be assessed by measuring liver volume on CT or 
MRI. A common method for volumetry is segmentation which includes the manual delineation 
of transversal CT or MRI images followed by interpolation of slices by an automatic algorithm. 14 
Clinical characterization
The natural course of PLD varies extremely among individual patients. Some patients develop 
symptomatic hepatomegaly, while others do not. Liver growth in PLD is estimated to be 
between 0.9-3.2% per year, based on results of placebo groups in clinical trials. 15-17 Of note, 
clinical trials have also shown that some patients have spontaneous reduction of liver volume 
while others have extreme increases. 17 
Progressive cyst growth has been associated with several risk factors. Previous cohort studies 
showed that the prevalence of liver cysts increases with age and that females have a higher 
risk to develop severe PLD. 2,6,18 In 1997, a prospective clinical trial treating postmenopausal 
women with estrogen, showed a significant increase in liver volume after treatment compared 
to no treatment. Prior pregnancies were a strong predictor of presence of hepatic cysts. 19 
However, this study included only 19 patients and these results have not been replicated 
since. 19 A recent individual pooled data analysis found that especially young females (≤48 
years) demonstrate progressive cyst growth, compared to older women and men. 20 These 
results might implicate an important role for female hormones in biogenesis of hepatomegaly. 
Finally, there is no evidence that ADPKD genotype is related to PLD phenotype. 21 For ADPLD, 
a genetic mutation in sec63 or PRKCSH was associated with symptomatic disease in a cross 
sectional analysis of 137 patients, although liver volume was not included in this analysis and 
no conclusions can be drawn about the association with severity of PLD in terms of volume. 2 
A small proportion of patients with progressive cyst growth and massive hepatomegaly, 
may develop symptoms and experience a reduced health-related quality of life. 22 Common 
symptoms are early satiety, abdominal distension and dyspnea. 14 For ADPKD patients, pain is 
assumed to be an important symptom and this might be related to kidney volume. 23 However, 
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Chapter 1
the exact relation of liver and kidney volume with symptom burden or health-related quality 
of life is not yet elucidated.
Due to the low prevalence of PLD, physicians are not exposed to large patients groups. 
Therefore, their knowledge on clinical course, treatment efficacy and prognosis can be limited. 
These difficulties impede research in mapping natural course of PLD. A registry would be useful 
to create a large cohort of patients in order to fill in these gaps in knowledge. 
Therapy 
Current therapies
Therapy is indicated in patients who suffer from symptomatic hepatomegaly. A clear definition 
of symptomatic hepatomegaly is lacking, as well as standards that guide us when to initiate 
therapy and which therapy to give to individual PLD patients. 24 As a result, there is a variability 
in treatment between patients in clinical practice.
Current therapies can be divided in experimental and non-experimental therapies. Non-
experimental therapies include a radiological therapy, aspiration sclerotherapy, and several 
surgical procedures such as fenestration, resection and liver transplantation. Aspiration 
sclerotherapy involves radiological cyst aspiration followed by administration of a sclerosing 
agent to destruct cyst wall. 1,25 Patients with 1 or 2 large (>5cm) symptomatic dominant cysts 
are good candidates for this procedure. Fenestration is a suitable therapy for patients with large 
(>10cm) cysts or multiple medium-sized cysts with large areas of non-cystic liver parenchyma. 
This is a surgical procedure that combines aspiration with deroofing of cysts. The advantage 
Figure 1. Flowdiagram for treatment strategy in PLD patients 1 [with author permission]
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
11
General introduction and outline
1
of this method beyond aspiration sclerotherapy is the possibility to treat multiple cysts in a 
single procedure. Hepatic resection can be applied to patients with livers that have at least one 
segment with predominantly normal liver parenchyma. This procedure is not often performed 
due to the rarely present phenotype and the high complication rate. The only curative therapy 
is liver transplantation, though in terms of risk and scarcity of donors this treatment strategy is 
not widely applied.1,25 Figure 1. shows a flow-diagram that might facilitate the choice of therapy.1
Experimental therapies
Most symptomatic patients do not fulfill the criteria for the above mentioned therapies. 
Conservative treatment entails pain medication and life style changes, though there is no solid 
evidence for these strategies. The risk of complications or recurrence with invasive therapies is 
high, and with the exception of liver transplantations they do not change natural course. This 
emphasizes the need for an effective, non-invasive therapy. 
Stimulation of cAMP results in cholangiocyte proliferation, and the discovery of this path-
way has led to the development of novel therapeutic approaches for treatment of PLD. 
Pharmacological inhibition of this signaling pathway by somatostatin analogues, has shown to 
be successful in reducing liver volume up to 5% after administration for 6-12 months. 15,26,27 
Octreotide and lanreotide both bind to somatostatin receptors expressed in cyst epithelium. 
These drugs reduce intracellular levels of cAMP and inhibit cholangiocyte proliferation and 
cyst fluid accumulation.28,29 Unfortunately, drawbacks of somatostatin analogues are side 
effects, patients unresponsiveness and costs. This highlights the need for other options. 
Ursodeoxycholic acid (UDCA) reduces cystogenesis by both increasing Ca2+ and decreasing 
cAMP levels in cystic cholangiocytes. Experimental evidence has shown that UDCA was able to 
inhibit proliferation of human cholangiocytes in vitro and hepatic cystogenesis in PCK rats, an 
animal model of PLD. 30,31
In conclusion, there are gaps in our understanding of the clinical profile of PLD and the 
response to various treatment options. The ultimate goal would be to develop an evidence-
based guideline on whom to treat, what to treat, when to initiate therapy and which therapy 
to give. We have investigated a number of specific objectives that will contribute to achieve 
this goal.
First, we need to elucidate the role of liver and kidney volume on symptom burden. We also 
need to gain more insight in determinants associated with severe PLD to create risk groups. 
Second, we need to identify factors that play a role in the treatment decision process. Finally, 
we need to find out whether UDCA is a successful non-invasive therapy for PLD. 
The aim of this thesis is to explore who is in need of therapy, who receives therapy and 
whether treatment with UDCA is an effective therapy for PLD.
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To address these questions, we have structured this thesis in three parts. For each part the 
hypothesis and rationale, research model and research questions will be presented.
1. Who should we treat and what should we target?
The main indication to initiate treatment in PLD patients is symptomatic hepatomegaly or 
severe PLD. The question is who develops severe PLD and who will be in need of treatment? 
Former studies have found evidence among patient-related risk factors for severe PLD such 
as age, female gender, estrogen use and pregnancies. 2,6,18,19 The effect of ADPLD genotype 
on PLD phenotype remains unclear. Recently, a cross-sectional study investigated the role 
of ADPKD genotype on PLD phenotype and failed to detect an association. The question is 
whether genotype-phenotype associations should be studied in a cross sectional manner. Our 
editorial gives an overview of the current knowledge among determinants associated with 
severe PLD (chapter 2). We used this to share our thoughts about future steps that are required 
to understand the relation between genotype and phenotype. 
When we know the population at risk for symptomatic hepatomegaly we need to discover what 
we should treat in order to prevent or reduce symptoms. Current and experimental therapies for 
severe PLD focus on reducing liver volume in order to diminish symptoms. 1 However, the role of 
liver volume in relation to symptom burden is not well understood. There is limited knowledge 
on the role of other factors such as medical history, in symptom burden. As a consequence, we 
do not know what and how strong the effect of volume reduction will be on symptom burden. 
This thwarts the understanding of the population who is most likely to benefit from treatment. In 
addition, the majority of PLD patients possesses renal cysts as well (ADPKD) which complicates 
the understanding of the relation between liver volume and symptom burden. Multiple studies 
have already tried to separate the effect of kidney and liver volume on symptom burden, but 
results are conflicting. 22,23,32,33 We hypothesized that in patients with ADPKD a combination of 
liver and kidney volume is a better predictor for symptom burden than liver or kidney volume 
alone. We also think that sex might be a confounder as women have a higher risk to develop 
hepatomegaly. If both renal and liver volume play a role in symptom burden, treatment should 
target both. A difference in association between volume and symptom burden between men 
and women would result in different treatment strategies for both sexes.
We chose to perform a cross-sectional analysis of patients with later stage ADPKD (chapter 3). 
We used baseline data of patients included in a multi-center, randomized, controlled clinical 
trial executed in the Netherlands. The advantage of this study model was the protocolised 
character of data collection. The selection of later stage ADPKD patients ensured that this 
population had a higher risk to be symptomatic and to have enlarged kidneys and livers. This 
facilitates to study the relation between organ enlargement and symptoms. We composed the 
following research questions:
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• What are risk factors for severe PLD?
• What is the effect of ADPKD genotype on PLD phenotype?
• What genotype-to-phenotype concepts should be studied to elucidate whether geno-
type influences phenotype variability?
• What are the most common gastro-intestinal symptoms in ADPKD patients?
• How many patients experience pain?
• What is the relation of kidney and liver volume with ADPKD-related symptom burden?
• Is the combination of kidney and liver volume stronger associated with ADPKD-related 
symptom burden than kidney and liver volume alone?
• What is the role of sex in the relation between kidney liver volume and symptom burden?
2. Who do we treat?
There are no clear guidelines for treatment of PLD, so who should actually be treated? Getting 
more insight in patients and disease related factors involved in treatment decision might help 
to find determinants associated with a more severe disease course. It also gives physicians 
insight in the process of treatment decision. We hypothesize that females have a higher 
likelihood to receive treatment, due to a higher risk of hepatomegaly. We also think that in 
the absence of clear guidelines for initiating therapy in PLD, the decision to treat depends on 
expertise and opportunities of physicians.
To establish a clinical characterisation of the population that we treat, a registry design 
was used to create a cohort of PLD patients. A registry is an excellent observational study 
method to collect clinical data from individual patients to study the clinical course of a rare 
disease, such as PLD. Prior to the development of our registry we studied literature to find out 
what fundamental aspects should be included in our database. We also interviewed several 
researchers deemed experts in the field of registry studies. We shared our experiences through 
a paper that reflects our thinking how to build a successful registry (chapter 4). The registry 
we created was an international database including PLD patients from two nationwide referral 
centers in Belgium and the Netherlands. We were able to perform a cross-sectional analysis on 
the role of patients characteristics, disease specific factors and center on treatment decision 
(chapter 5). Our registry paper and cross-sectional analysis will help to answer the following 
research questions:
• What are the main aspects of a clinical registry?
• Which properties ensure a successful registry?
• How many patients included in our registry receive invasive treatment for PLD?
• Which patient characteristics and disease factors are associated with invasive treatment?
• What is the role of center in treatment decision and the choice for a specific therapy?
• Which determinants are associated with specific invasive treatment modalities?
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3. A novel therapy for PLD?
Current therapies for PLD are mainly invasive, have high complication rates while the chance of 
success is difficult to predict. In clinical practice, a large group of patients is symptomatic while 
liver is moderately enlarged. In those cases, invasive therapy is often a step too far. Therefore 
we need a non-invasive treatment for PLD. An animal model of rats suffering from polycystic 
livers has shown that UDCA inhibits proliferation of polycystic human cholangiocytes in vitro 
and hepatic cystogenesis in vivo.31 Therefore, we hypothesized that UDCA was effective in 
reducing TLV, liver cyst volume and symptoms in PLD patients.
The best way to assess the efficacy of UDCA on reducing TLV in PLD was to design a randomized 
controlled trial (chapter 6a). As we learned from our registry experiences, international 
collaboration is essential in the field of rare diseases. Therefore we designed this trial in 
collaboration with Spain and created a multicenter, international trial including three tertiary 
centers for PLD. Collaboration with tertiary centers facilitates identification of patients with 
symptomatic hepatomegaly, the study population that is in need of therapy. This randomized 
controlled trial will help to answer the following research questions (chapter 6b):
• Does UDCA affect TLV in PLD?
• What is the effect of UDCA on symptoms in PLD?
• What is the effect of UDCA on health-related quality of life in PLD?
• Is UDCA safe for PLD patients?
• What is the effect of UDCA on liver cyst volume in PLD?
• Does UDCA have a different effect on TLV in ADPKD and ADPLD patients?
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In the issue of Nephrology Dialysis and Transplantation Chebib et al. 1 analyze whether muta-
tions in genes responsible for autosomal dominant polycystic kidney disease (ADPKD) contri-
bute to its most frequent extrarenal phenotype: polycystic liver disease (PLD). In order to do 
so, they searched for mild (PKD2) and severe mutations (truncating and non-truncating PKD1) 
in a large cohort of ADPKD patients. They used liver imaging data to establish genotype-
phenotype correlations. Though PKD genotype and renal phenotype are strongly related in 
ADPKD patients, this was clearly not the case for PKD genotype and PLD phenotype. These 
observations raise a number of questions. Is a cross- sectional analysis the best model to study 
genotype-phenotype associations? If PKD genotypes are not, which are bona fide risk factors 
for progressive liver enlargement in ADPKD? What future steps are required to elucidate 
determinants for liver cyst growth in ADPKD patients? 
Polycystic liver disease
PLD is characterized by the presence of cysts throughout the liver and caused by mutations 
in specific genes such as PKD1, PKD2, PRKCSH, Sec63 and LRP5. 2,3 Two genetically distinct 
disorders are associated with PLD, ADPKD and autosomal dominant polycystic liver disease 
(ADPLD). In ADPLD patients, PLD is the primary phenotype, while kidney cysts are ubiquitous 
in ADPKD. 4,5 Hepatic cysts are the most common extra-renal manifestation in ADPKD with a 
prevalence of 69% among women and 79% among men, and prevalence increases with age. 
6 There is a wide range in liver size and liver growth rate among patients, but also between 
members from the same family who share identical genetic mutations. 2,7 In a small subset of 
patients, PLD leads to symptoms such as abdominal pain and early satiety, reduced health-
related quality of life (HRQL) and complications such as infections or cyst rupture. 4,8 Reduction 
in liver volume is thought to improve HRQL and symptoms, although the relation between both 
elements remains unclear. Indeed, a study in 92 PLD patients did not establish a correlation 
between liver volume and physical component score of a generic short-form health survey. 8 
Genotype
ADPKD is a caused by mutations in PKD1 and PKD2. Both genes are responsible for almost 
all ADPKD cases. PKD1 and PKD2 encode two transmembrane proteins, polycystin-1 and 
polycystin-2, that represent a subfamily of transient receptor potential channels and are located 
at the primary cilium. We have witnessed considerable progress towards our understanding of 
mechanisms that are involved in cyst growth in ADPKD. What had been established was that 
PKD1 or PKD2 germline mutations alone are insufficient for cystogenesis. Molecular studies 
of cyst epithelia found that the second affected ADPKD allele in cystic cells is often lost or 
mutated. In addition, clinical observations are consistent with a high intrafamilial phenotypic 
variation in related individuals with identical mutations. Indeed, somatic hit mutations in PKD1 
or PKD2 have been identified in liver and kidney tissues of ADPKD patients, supportive of a 
second-hit model. 9-12 
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Studies in ADPLD are in line with this concept. In ADPLD cyst tissue, loss of heterozygosity of 
the PRKCSH and Sec63 allele is present with a frequency that appears to depend on the gene 
affected in germline. 9,10 There is no evidence that the gene (PRKCSH, LRP5 or Sec63) or type 
of genetic mutation affects ADPLD phenotype. 13 One could hypothesize that patients with a 
severe phenotype are more susceptible to acquire somatic mutations than patients with a mild 
phenotype, or that patients with mild phenotypes have protective mechanisms that render the 
“resistance” against somatic mutations. The (unaddressed) issue central to this theme is, which 
factors drive somatic mutations?
In the current study, stratification of ADPKD patients according to PKD genotypes suggests that 
a clear relation between PKD genotype and PLD phenotype is absent. The question is whether 
a retrospective cross-sectional cohort study is the best design to assess genotype-phenotype 
associations. The authors limited their selection to patients with known PKD1/PKD2 genotype, 
potentially introducing selection bias. Molecular genetic testing is not part of routine clinical 
practice but may be considered in cases with equivocal or atypical renal imaging findings (e.g. 
markedly asymmetric PKD, renal failure without significant kidney enlargement) or in ADPKD 
patients without a positive family history. 14 In addition, by including families, their dataset 
was enriched with patients who had similar genotypes, limiting the spread of the mutational 
spectrum and possibility to detect meaningful associations. From a phenotype perspective, 
patients were included if MRI/CT images were available. As per guidelines routine hepatic 
imaging is not recommended for follow-up of ADPKD patients; this may have led to the 
selection of a study population at the extreme ends of severity with respect to renal and/or 
hepatic phenotype. 14 Again, this would make it challenging to detect meaningful associations. 
The overall majority had PKD1 mutations, which certainly limits the chance of detecting 
associations with PKD2. 
It is likely that several disrupted gene products are involved in the considerable phenotype 
variability in PLD patients. The presence of modifier genes or epigenetic factors might contri-
bute to this. 15 Modifier genes are able to modulate cystogenesis by determining the quality or 
quantity of second hits. The evidence for loss-of-heterozygosity regions in ADPLD cyst tissue 
might indicate that modifier genes affect cystogenesis in PLD. 7 In ADPKD patients, candidate 
gene or genome-wide association studies have not yet identified modifier genes for ADPKD 
phenotype. Larger international replication studies are needed to confirm these results. 15 
Another concept that might explain differences in phenotype expression in PLD is epigenetic 
modulation, a phenomenon that changes gene expression and activity without modifying 
DNA sequence. 16 Only recently evidence surfaced that epigenetics might be associated with 
renal pathogenesis in ADPKD. In a cohort of ADPKD and non-ADPKD individuals, genome-wide 
profiling showed that hypermethylation of PKD1 and other genes involved in ion transport and 
cell adhesion in ADPKD patients resulted in downregulated expression and cystogenesis. These 
data suggest that epigenetic silencing might play a key role renal cyst development. 17,18 This 
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has never been studied in PLD, and further research needs to elucidate whether epigenetics 
have a main role in the complex of pathways involved in genotype-to-phenotype expression. 
Patient factors 
Patient factors that influence progression of PLD are age, female gender, oestrogen use and 
pregnancies. 13,19,20 There is an age-dependent effect, and the prevalence of hepatic cysts in 
a large cohort (n = 230) of early ADPKD rose from 58% in patients 15-24 years of age to 
94% in 35-46 years old patients. 20 Clinical trials that included placebo groups have illustrated 
that particularly young women (≤48 years) demonstrate progressive cyst growth (4.8% in 6-12 
months), compared with stagnant liver growth in women older than 48 years (0.6% in 6-12 
months), and men (-0.1% in 6-12 months). 21 In this issue of Nephrology Dialysis Transplantation, 
Chebib et al. 1 confirmed these results; age younger than 48 yrs was associated with an annual 
growth rate of 2.65%, compared with 0.09% in women ≥48 years (P<0.001). In contrast, this 
age effect was not seen in men (2.28% vs. 0.8%, P=0.18). The concept that oestrogens are 
positive modulators of cholangiocyte proliferation is supported by a clinical trial that treated 
postmenopausal women with exogenous oestrogen. Liver volume significantly increased under 
oestrogen treatment (7±12% vs. 2±8%, P=0.03). 19 Additionally, a history of pregnancies is a 
strong predictor of presence of hepatic cysts. 19,22 A retrospective cohort study in 275 female 
PLD patients showed no effect of pregnancy or exogenous oestrogen on liver volume, although 
this difference in results might be explained by lower oestrogen content of contemporary 
contraceptives compared with the earlier days. Chebib et al. 1 also found no relation between 
pregnancy and liver volume. 6 In clinical practice, we still remain cautious in prescribing oral 
contraceptives or postmenopausal oestrogen to women with PLD. In our clinical practice, we 
advice patients to seek alternative contraceptives such as an intrauterine device, and explain 
the possible influence of pregnancies on liver volume. 
Conclusion
Specific genes are associated with development of PLD in ADPKD and ADPLD patients. 
Currently, there is no evidence for a role of genotype in the phenotypic expression of PLD. 
The present study highlights the importance of assessing effect of genotype on phenotypic 
disease characteristics. It also demonstrates issues that come along with retrospective cohort 
studies. Patient-related factors such as age, sex, oestrogen use and pregnancies influence 
natural course (Figure 1). Nevertheless, it is still impossible to predict natural course in 
individual patients that impedes treatment of PLD. Who needs therapy and when is the best 
time to initiate therapy? These are the main questions for physicians who treat PLD patients. To 
answer these questions, we need to understand the factors that are involved in the phenotypic 
variability of PLD. Assuming the two-hit concept to be true, a model should be created that 
reveals the relation between factors that manipulate somatic mutations and eventually lead 
to different phenotypes. Epigenetic alterations and modifier genes might be key modulators. 
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Figure 1. Genetic and patient factors involved in PLD.
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ABSTRACT
Background & aims
There is an ongoing debate if and how kidney and liver volume are associated with pain and 
gastrointestinal symptoms in ADPKD patients. Since both kidney and liver volume could inter-
act, we investigated whether combined total kidney and liver volume had stronger associations 
with ADPKD-related pain and gastrointestinal (GI) symptoms than the volumes of the organs 
separately. 
Methods 
We used baseline data from the DIPAK-1 study which included ADPKD patients with an eGFR 
between 30-60 mL/min/1.73m2. MR imaging was performed to measure height adjusted total 
kidney volume (hTKV), total liver volume (hTLV) and the combination of both (hTKLV). 
Results
309 ADPKD patients were included with a mean age of 48±7 years, 53% female, eGFR 50±11 
mL/min/1.73m2 and median hTKV, hTLV and hTKLV of 1095 [758-1669], 1173 [994-1523] and 
2496 [1972-3352] mL/m, respectively. ADPKD-related pain and GI symptoms were present 
in respectively 27.5% and 61.2% of patients. Sex was no effect modifier in the association 
between kidney and/or liver volume, and symptom burden. hTKLV and hTLV were significantly 
associated with pain and GI symptoms, whereas hTKV was not. Model testing revealed that 
the associations of pain and GI symptoms with hTKLV were significantly stronger than with 
hTKV (p=0.04 and p=0.04, respectively), but not when compared to hTLV (p=0.2 and p=0.5, 
respectively). 
Conclusions
This study indicates that combined kidney and liver volume was associated with the presence 
and severity of pain and GI symptoms in ADPKD, with a more prominent role for hTLV than for 
hTKV.
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INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive renal 
cyst formation and the majority of patients also have liver cysts (>94%) 1. During lifetime 
kidney and liver volume increase, leading to distension of the renal and hepatic capsules, and 
compression of adjacent organs 2. Consequently, a substantial proportion of ADPKD patients 
suffers from pain and gastrointestinal symptoms, such as abdominal fullness and early satiety3-6.
There is an ongoing debate if and how kidney and liver volume are associated with pain and 
gastrointestinal symptoms. A number of studies have investigated symptom burden in ADPKD 
patients 5,7-9. The largest of these studies did not find an association between kidney volume 
and pain, except in a small subgroup with very large kidneys 5. Another study concluded that 
quality of life was not different between patients with a total kidney volume (TKV) larger or 
smaller than 1000 mL, but the effect of liver volume was not assessed 8. Two studies that 
analyzed the effect of liver volume on quality of life, showed conflicting results, with one study 
finding no relation and the other a significant, but weak association between liver volume and 
symptom burden 10,11. Of note, all aforementioned studies varied in the use of height or non-
height adjusted kidney and liver volumes 5,7-10. In terms of disease progression height adjusted 
total kidney volume (hTKV) has been shown to be more closely related to the rate of disease 
progression than non-height adjusted TKV 12. The question arises whether the conflicting data 
in literature may be explained by the fact that sometimes height and sometimes non-height 
adjusted volumes were used to test correlations with symptom burden.
Another factor that potentially affects symptom burden is a difference in sex. In literature fe-
males are overrepresented among cohorts of patients with symptomatic ADPKD 13,14. This is 
usually attributed to the presence of a more severe liver phenotype in females 15. On the other 
hand, pain sensitivity has been suggested to be greater among females, and females are more 
likely to report gastrointestinal symptoms when compared to males 16-18. To our knowledge, it 
has not been investigated whether higher symptom burden in females with ADPKD is caused 
by differences in reporting by sex in general, or by differences in kidney and/or liver size 
between both sexes.
Since both kidney and liver volume drive intra-abdominal volume, it is reasonable to assess 
the association of combined kidney and liver volume with ADPKD-related pain and gastro-
intestinal symptoms 19. Therefore, we investigated in a large cohort of ADPKD patients whether 
combined kidney and liver volume is more strongly associated with ADPKD-related pain and 
gastrointestinal symptoms than kidney or liver volume alone, secondly whether there is a 
differences in the strength of this association between males and females, and thirdly whether 
height adjusted volumes are more strongly associated with pain and gastrointestinal symptoms 
than non-height adjusted volumes.
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MATERIALS AND METHODS
Patients and study design
Baseline data were used from the DIPAK-1 study, an investigator driven, multi-center, randomized, 
controlled clinical trial that included ADPKD patients with an estimated glomerular filtration 
rate (eGFR) between 30-60 mL/min/1.73m2 and age 18-60 years. Patients were enrolled at 4 
University Medical Centers in the Netherlands (Groningen, Leiden, Nijmegen and Rotterdam) 
between June 2012 and March 2015. ADPKD diagnosis was based on the modified Ravine 
criteria 20. Exclusion criteria were among others, concomitant illnesses likely to confound the 
natural decline of renal function in ADPKD, for example diabetes mellitus. Details of the study 
protocol have been published elsewhere 21. The Medical Ethics Committee of the University 
Medical Center Groningen approved the protocol of the DIPAK-1 study that was conducted 
in accordance with the International Conference of Harmonization Good Clinical Practice 
Guidelines and in adherence to the ethics principles that have their origin in the Declaration of 
Helsinki (METc2012/060). All patients gave written informed consent.
Data collection, measurements and definitions
Evaluations were performed in all patients at baseline including standardized interviews, 
phy sical examination, collection of blood samples and MR imaging. During the interviews 
information was gathered about demographics, medical history, pain and gastrointestinal 
symptoms. Renal pain was defined as pain or discomfort located in the flank, the lower back 
or abdomen. Liver pain was defined as pain or discomfort located in the right upper abdomen, 
behind or below the rib cage. The severity of renal and/or liver pain during the last 4 weeks 
was assessed on a 1-10 scale (1=no pain, 10=worst possible pain), and presence of renal or 
liver pain was defined as a score >2. Since it is difficult to distinguish between renal and liver 
pain, we used a composite score for ADPKD-related pain. Presence of ADPKD-related pain was 
defined as a composite score of >2 on either renal or liver pain. For severity of ADPKD-related 
pain the highest score on either renal or liver pain was used. The presence of gastrointestinal 
symptoms over the last 4 weeks was recorded via the gastrointestinal symp toms questionnaire 
22 (Supplementary file 1). This questionnaire contains 11 items including: lower and upper 
abdominal pain, heartburn, regurgitation, nausea, vomiting, loss of appetite, early satiety, 
dyspnea, increase of abdominal waist and involuntary weight loss. All symptoms were assessed 
using a 7-point Likert scale, ranging from 1 (“none”) to 7 (“severe”). Symptom severity sum 
score was calculated by summing all scores and converting it to a score from 0 to 100 22. 
Presence of gastrointestinal symptoms was defined as a score of >2 on at least one of 11 
gastrointestinal symptoms.
Serum creatinine was reported and used to estimate GFR (applying the CKD-EPI equation) 23. All 
patients underwent a MRI to assess kidney and liver volumes by the manually tracing method 
using the commercially available software Analyze Direct 11.0 (Analyze Direct, Inc., Overland 
Park, KS, USA). Kidney and liver volumes were calculated from the set of contiguous images 
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by summing the products of the area measurements within the kidney or liver boundaries 
and slice thickness. Details of the imaging protocol have been reported previously 21. hTKV, 
height adjusted total liver volume (hTLV) and combined total kidney liver volume (hTKLV) were 
calculated as total organ volume in mL divided by height in meters. 
Statistical analyses
We performed a cross-sectional analysis of the baseline data of the DIPAK-1 study. Baseline 
characteristics were calculated for the overall population and stratified for patients ex-
periencing ADPKD-related pain, experiencing gastrointestinal symptoms and sex. Parametric 
variables are expressed as mean ± standard deviation (SD), non-parametric variables as median 
± interquartile range [IQR]. Differences in baseline characteristics between groups were 
calculated with a Chi-square test for categorical data, and for continuous data with Student’s 
t-test or a Mann-Whitney U test in case of non-parametric data.
To investigate whether organ volume correlated with ADPKD-related pain and gastrointestinal 
symptoms, univariate and multivariate linear regression analyses were performed. hTKV, hTLV 
and hTKLV were logarithmic transformed to fulfill the requirement of normal distribution of the 
residuals for regression analysis. The multivariate linear analyses were subsequently adjusted 
for age and eGFR to correct for disease severity. To investigate differences between males and 
females the variable sex was added to the regression analysis. To explore whether associations 
between organ volume (i.e. hTKV, hTLV and hTKLV) and symptom burden (i.e. ADPKD-related 
pain and gastrointestinal symptoms) were different between males and females, interaction 
was tested by adding product terms (sex times volume) as independent variable to the models.
We used bootstrapping (2000 times) to investigate whether the association of hTKLV with 
ADPKD-related pain and gastrointestinal symptoms was stronger than the associations between 
either hTKV or hTLV, and ADPKD-related pain and gastrointestinal symptoms. In all models we 
corrected for disease severity by adjustment for sex, age and eGFR. As sensitivity analysis, 
we restricted the analysis of the associations between organ volume and symptom burden to 
patients with extremely enlarged kidney volumes (hTKV >1000 mL/m), as defined previously 
in literature 5. Lastly, bootstrapping was performed to analyze whether height adjusted volume 
models were more strongly associated with pain and gastrointestinal symptoms than non-
height adjusted volume models. All analyses were performed using SPSS (software version 
22.0, Chicago, IL, USA) and STATA (Version 14 StataCorp SE) statistical software, and a two-sided 
p<0.05 was considered to indicate statistical significance.
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RESULTS
Patient characteristics
We enrolled 309 ADPKD patients in our study, of which 53% were female with a mean age of 
48±7 years. Following our inclusion criteria all patients had an impaired renal function, with 
a mean eGFR of 50±11 mL/min/1.73m2. Blood pressure was on average well controlled and 
almost all patients used antihypertensive medication (91.2%). Median height adjusted total 
kidney volume (hTKV), total liver volume (hTLV) and combined total kidney liver volume (hTKLV) 
were respectively 1095 [758-1669] mL/m, 1173 [994-1523] mL/m and 2496 [1972-3352] 
mL/m. Liver cysts were present in the large majority of patients (93.2%).
ADPKD-related pain and gastrointestinal symptoms
ADPKD-related pain was reported by 27.5% of the study population (renal pain: 24.9% and 
liver pain: 11.3%) (Table 1). Pain was more common in females than in males. Age and eGFR 
did not differ between patients with and without pain, while a history of renal pain, liver pain, 
urinary tract infection, renal cyst infection, liver cyst infection and macroscopic hematuria were 
more common in those who reported pain. Liver cysts were also more common in patients 
experiencing ADPKD-related pain. Larger hTLV and hTKLV were associated with pain, whereas 
hTKV was not.
A total of 61.2% of the ADPKD patients experienced gastrointestinal symptoms, with females 
being overrepresented in patients reporting these symptoms (Table 1). Age and eGFR were 
not different between patients with or without gastrointestinal symptoms. Presence of gastro-
intestinal symptoms was associated with a history of renal pain, liver pain, urinary tract 
infection, renal cyst infection and renal surgery. Out of the 11 gastrointestinal symptoms that 
were assessed, the most frequently reported symptom was early satiety (32.0%), followed by 
increased abdominal volume (25.2%), dyspnea (24.6%), heartburn (22.7%) and regurgitation 
(18.4%) (Table 2).
Association of kidney and liver volume with pain and gastrointestinal symptoms
To investigate whether associations between volumes (hTKV, hTLV and hTKLV) and symptom 
burden (ADPKD-related pain and gastrointestinal symptoms) were sex dependent, we tested 
the interaction between these characteristics. No significant interaction with sex was found, 
indicating that all associations could be tested across the complete study population and 
that stratification by sex was not necessary. hTKV was not associated with severity of ADPKD-
related pain in the overall population (R=0.05, p=0.44) (Figure 1). In contrast, hTLV and hTKLV 
were both correlated with ADPKD-related pain (R=0.20, p<0.001 and R=0.23, p<0.001). 
After adjustment for disease severity, by correction for age, sex and eGFR, these associations 
remained significant (R=0.23, p<0.001 and R=0.20, p<0.001, respectively). The hTKLV model 
was also more strongly associated with pain than the hTKV model (p=0.04), whereas this was 
not the case for the hTLV model (p=0.2).
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Figure 1. Associations of height adjusted Total Kidney Volume (hTKV), Total Liver Volume (hTLV) and 
combined Total Kidney Liver Volume (hTKLV) with ADPKD-related Pain Score (1-10).
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We then tested whether kidney and liver volume were associated with gastrointestinal sum 
score. No association was found for hTKV (R=0.10, p=0.09), whereas hTLV and hTKLV were 
both associated with the gastrointestinal sum score (R=0.23, p<0.001 and R=0.23, p<0.001, 
respectively) (Figure 2). Again, the association with gastrointestinal symptoms was significantly 
stronger for the model containing hTKLV compared with the model containing hTKV (p=0.04), 
but not compared with the model with hTLV (p=0.5).
Of note, we performed a sensitivity analysis to test whether these associations were different 
in patients with larger kidneys (hTKV >1000 mL/m). Essentially the same results were found as 
in the initial analysis; hTLV and hTKLV were, and hTKV was not associated with ADPKD-related 
pain and gastrointestinal symptoms.
Differences in symptom burden between males and females
Renal and liver pain were present in 30.1% and 17.8% of females while this only accounted for 
19.2% and 4.1% in males (p=0.04 and p<0.001, respectively). In case a patient experienced 
renal or liver pain, the severity of pain was similar among males and females. Gastrointestinal 
symptoms were more prevalent among females. The following symptoms were reported more 
frequently by females: abdominal pain, nausea, early satiety and an increased abdominal 
volume, compared to males (Table 2). Gastrointestinal symptoms as expressed in the gastro-
intestinal sum score were more severe in females than in males (17.6 vs. 9.0, p<0.001). 
Females had larger hTLV and smaller hTKV than males (hTLV: 1249 [1034-1901] vs. 1130 [967-
1336] mL/m, p<0.001 and hTKV: 923 [604-1330] vs. 1314 [935-2145] mL/m, p<0.001). hTKLV 
did not differ between both sexes (females: 2424 [1939-3213] mL/m, males 2537 [2065-
3547] mL/m, p=0.2). Female sex was positively associated with symptom burden in ADPKD 
patients, but after adjustment for hTLV, this association lost significance.
Height adjusted versus non-height adjusted models
No difference was observed in the association with symptoms between the models with either 
hTKV or TKV (p=1.0), whereas the models with hTLV and hTKLV had stronger associations with 
pain than the models with TLV and TKLV (p=0.02 and p=0.01, respectively). For gastrointestinal 
sum score, similar results were found. hTLV and hTKLV models were more strongly associated 
with gastrointestinal symptoms than non-height adjusted models (p=0.01 and p=0.01, respec-
tively), which did not account for the hTKV model (p=1.0). Of note, the results of correlation 
analyses of ADPKD-related pain and gastrointestinal symptoms with non-height adjusted TKV, 
TLV and TKLV, were essentially similar to the results of the primary analyses with hTKV, hTLV and 
hTKLV (Table 3 and Supplementary Table 1). The relations between organ volume and symptom 
burden still existed, but were less strong compared to the height adjusted models (Table 3).
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Figure 2. Associations of height adjusted Total Kidney Volume (hTKV), Total Liver Volume (hTLV) and 
combined Total Kidney Liver Volume (hTKLV) with gastrointestinal sum score (0-100).
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Table 2. Prevalence and severity of ADPKD-related pain and gastrointestinal symptoms overall and 
stratified for sex.
Overall
% or median 
± IQR
Males
% or median 
± IQR
Females
% or median 
± IQR P-val.
History of pain 
Renal related pain 47.6% 43.2% 51.5% 0.14
Liver related pain 12.0% 2.1% 20.9% <0.001
Renal or liver related pain 50.8% 45.2% 55.8% 0.06
Presence of pain
Renal related pain 24.9% 19.2% 30.1% 0.04
Liver related pain 11.3% 4.1% 17.8% <0.001
Renal or liver related pain 27.5% 19.9% 34.4% 0.006
Severity of present pain 
Renal related pain 4 [3-6] 3.5 [3.0-6.0] 5.0 [3.0-6.0] 0.3
Liver related pain 5 [4-7] 4 [3.8-4.8] 6 [4-7] 0.1
Renal or liver related pain 4 [3-7] 4.0 [3.0-6.0] 5.0 [3.0-7.0] 0.2
Gastrointestinal symptoms
Lower abdominal pain 14.9% 9.6% 19.6% 0.02
Upper abdominal pain 17.8% 9.6% 25.2% <0.001
Heartburn 22.7% 22.6% 22.7% 0.9
Regurgitation 18.4% 17.8% 19.0% 0.9
Nausea 13.6% 6.8% 19.6% 0.001
Vomiting 3.2% 2.1% 4.3% 0.3
Loss of appetite 16.2% 10.3% 21.5% 0.01
Early satiety 32.0% 19.9% 42.9% <0.001
Dyspnea 24.6% 19.2% 29.4% 0.05
Increasing abdominal volume 25.2% 16.4% 33.1% 0.001
Involuntary weight loss 2.9% 1.4% 4.3% 0.1
Severity of present GI symptoms
GI- sum score 12.0 [8.0-21.0] 9.0 [4.5-16.7] 17.6 [15.2-23.1] <0.001
Abbreviations are: GI, gastrointestinal. Denominators depend on the number of patients who provided an 
answer for a specific question in the questionnaire. Renal and liver pain measured on scale 1-10 (1= no 
pain); GI-sum score ranging from 0-100. (0 = no symptoms).
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Table 3. Associations of height adjusted kidney and liver volumes with pain and gastrointestinal symptoms. 
hTKV hTLV hTKLV
R P-val. R P-val. R P-val.
History of pain
Renal related pain 0.10 0.1 0.15 0.01 0.22 <0.001
Liver related pain -0.06 0.3 0.30 <0.001 0.20 0.001
Renal or liver related pain 0.12 0.1 0.21 <0.001 0.27 <0.001
Presence of pain
Renal related pain 0.07 0.2 0.16 0.01 0.21 <0.001
Liver related pain 0.01 0.8 0.25 <0.001 0.21 <0.001
Renal or liver related pain 0.06 0.3 0.21 <0.001 0.24 <0.001
Severity of present pain 
Renal related pain 0.04 0.5 0.14 0.02 0.17 0.003
Liver related pain 0.04 0.5 0.27 <0.001 0.26 <0.001
Renal or liver related pain 0.02 0.8 0.20 <0.001 0.22 <0.001
Gastrointestinal symptoms
Lower abdominal pain 0.06 0.3 0.10 0.1 0.09 0.1
Upper abdominal pain 0.03 0.6 0.22 <0.001 0.19 0.001
Heartburn 0.15 0.01 0.05 0.4 0.13 0.03
Regurgitation 0.12 0.03 0.14 0.02 0.15 0.01
Nausea -0.04 0.5 0.22 <0.001 0.11 0.05
Vomiting -0.02 0.8 0.13 0.03 0.09 0.1
Loss of appetite 0.01 0.8 0.18 0.002 0.16 0.01
Early satiety 0.06 0.3 0.21 <0.001 0.21 <0.001
Dyspnea 0.06 0.3 0.14 0.02 0.11 0.1
Increasing abdominal volume 0.12 0.03 0.15 0.01 0.22 <0.001
Involuntary weight loss -0.02 0.7 0.08 0.2 0.00 1.0
Severity present gastrointestinal 
symptoms
GI- sum score 0.10 0.1 0.23 <0.001 0.23 <0.001
Abbreviations are: hTKV, height adjusted total kidney volume; hTLV, height adjusted total liver volume; 
hTKLV, height adjusted total kidney liver volume; GI, gastrointestinal. hTKV, hTLV and hTKLV were log 
transformed. Denominators depend on the number of patients who provided an answer for a specific 
question in the questionnaire. Renal and liver pain measured on scale 1-10 (1= no pain); GI-sum score 
ranging from 0-100. (0 = no symptoms).
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DISCUSSION
This study showed that both hTKLV and hTLV were moderately associated with pain and 
gastrointestinal symptoms in patients with later stage ADPKD, while hTKV was not. Other 
patient related characteristics, such as a history of urinary tract infection, renal cyst infection, 
liver cyst infection and macroscopic hematuria, were also associated with symptom burden. 
We found that females more frequently suffered from symptoms than males. However, sex 
was not an effect modifier in the relation between organ volume and symptoms and the 
higher symptom burden in women seems to be explained by their larger hTLV. In addition, the 
models containing height adjusted organ volumes were more strongly associated with pain 
and gastrointestinal symptoms compared to non-height adjusted models.
The general assumption is that a large kidney volume in ADPKD plays a role in causing pain 2. 
Interestingly, two studies that investigated the association between kidney volume and pain, 
did not confirm this assumption 5,8. The authors found that total kidney volume did not differ 
between those patients taking or not taking analgesics8. Only at the extreme of renal volumes 
in ADPKD (hTKV >1000 mL/m), an association between kidney volume and pain was found 5. 
In our study no association was found between hTKV and pain in the overall study population, 
nor in patients with very large kidneys. The present data add therefore to the evidence that the 
link between hTKV and pain is weak or even absent.
Previous studies found inconsistent results regarding the relation between liver volume and 
symptom burden. One study by Hogan et al, that included patients with early stage ADPKD 
(eGFR >60 mL/min/1.73m2), found an association between liver volume and reduced quality 
of life 10. However, another study found no such relation in 92 patients with polycystic liver 
disease, of whom 67% had ADPKD 11. Of note, this latter study included only patients with 
symptomatic polycystic liver disease, which makes finding associations between symptoms 
and liver volume population difficult. Our results suggest, in accordance with the results of 
Hogan et al, that liver volume in ADPKD contributes significantly to symptom burden, as both 
hTLV and hTKLV were associated with pain and gastrointestinal symptoms. The reason why liver 
volume seems to play a more important role in causing symptoms than kidney volume cannot 
be concluded from the present data. However, we hypothesize that organ location might be 
important. The liver has a position more closely to other intra-abdominal organs than the 
kidneys, that are located retroperitoneal. An increase in liver volume may consequently lead 
to more compression of adjacent tissues (i.e. stomach, intestines and lungs) than an increase in 
kidney volume, causing symptoms such as dyspepsia, early satiety, dyspnea and pain 4. 
Only one previous study has investigated the role of combined total kidney liver volume on 
patient reported outcome measures and  found no association with health related quality of 
life 7. Of note, kidney and liver volumes were available in only 31 out of 219 included patients 
(of which 21 were on dialysis) and the lack of significant associations may be due to the small 
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sample size. In contrast, we found significant association between hTKLV, hTLV and symptoms. It 
should be noted, however, that the strength of these associations was moderate. This suggests 
that symptom burden is multifactorial and that other factors may contribute 7. Potential 
other determinants may include coping mechanisms and comorbidity, such as a history of 
urinary tract infection, renal cyst infection, liver cyst infection and macroscopic hematuria, 
which according to our results, were also related to current ADPKD-related symptom burden. 
Adequate management of these events may be indicated to reduce the presence of symptom 
burden in ADPKD.  
Our data indicate a gender disbalance in prevalence and severity of ADPKD-related pain and 
gastrointestinal symptoms. This is in accordance with earlier studies that found that females 
more frequently reported pain, used analgesics and were more impaired in their physical 
activities compared to males 5. The same observation is true for the general population, 
where females report pain and gastrointestinal symptoms more frequently 16-18. Surprisingly, 
sex was no effect modifier in the relation between volumes and symptom burden in our 
study. As expected, females had larger hTLV compared to males, and when adjusted for hTLV, 
variations in symptom burden between males and females disappeared. Based on these data 
we hypothesize that the higher symptom burden in women could be explained by their larger 
hTLV, though it might be that women experience more pain in general, compared to men. 
Despite these findings, physicians have to realize that symptomatic polycystic liver disease 
will mainly be present in females, as estrogens stimulate liver cyst growth 24,25. Therefore the 
use of estrogens, such as in oral contraceptives, should be discouraged in symptomatic female 
ADPKD patients.
In symptomatic ADPKD patients, therapies are indicated that can slow cyst growth in both 
kidneys and liver. The TEMPO 3:4 trial demonstrated that tolvaptan, a vasopressin V2 receptor 
antagonist, decreased the rate of growth in total kidney volume26. This study also suggested 
that tolvaptan had a positive effect on acute renal pain events26. In contrast to the beneficial 
effect on renal cyst growth, tolvaptan presumably has no effect on liver cyst growth because 
the V2 receptor is not expressed in liver tissue. Our results suggest that in order to effectively 
reduce ADPKD-related symptom burden, therapy should also target liver cysts. Somatostatin 
analogues have been shown to reduce liver growth rate are and symptoms in ADPKD patients 
with severe polycystic liver disease 13,14,27. These agents also hold promise to reduce the rate 
of growth of total kidney volume 13,28 and the rate of renal function decline in ADPKD patients 
29. Somatostatin analogue therapy may therefore become a treatment option in ADPKD 
patients who suffer from pain and gastrointestinal symptoms, but this issue needs additional 
study before somatostatin analogues can be prescribed in clinical practice. Two randomized 
controlled trials are ongoing to test the efficacy of somatostatin analogues to delay disease 
progression and reduce symptom burden in ADPKD 21,30. 
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A limitation of our study is that it is performed in the setting of a randomized controlled trial 
with specific inclusion criteria for age (18-60 years) and renal function (eGFR 30-60 mL/
min/1.73m2).This may make extrapolation of our findings to the general ADPKD population 
difficult. However, we observed that neither ADPKD-related pain, nor gastrointestinal symptoms 
were associated with renal function, suggesting that our results may be valid for the general 
ADPKD population. The main strength of our study is the systematic and prospective nature of 
data collection, that resulted in a well-phenotyped population.
In conclusion, we found that combined kidney and liver volume is associated with pain and 
gastrointestinal symptoms in ADPKD, with a more prominent role for liver volume than for 
kidney volume. It should be noted, however, that other determinants, such as a history of 
urinary tract infection, renal cyst infection, liver cyst infection and macroscopic hematuria, 
also seem to be of importance in determining symptom burden in ADPKD. Height adjusted 
organ volumes were more strongly associated with symptom burden compared to the non-
height adjusted organ volumes, emphasizing the relevance of height adjustment to assess 
associations with symptom burden. Female ADPKD patients more often experienced pain and 
gastrointestinal symptoms than males. This sex difference could be explained by larger liver 
volumes in females compared to males. Lastly, our results implicate that physicians should be 
aware of the role of liver volume in symptomatic ADPKD and that efforts to reduce symptom 
burden should target especially liver volume.
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SUPPLEMENTARY FILES
Supplementary File 1. Gastrointestinal symptoms questionnaire
Did you experience during the 
last 4 weeks None Mild
Mode- 
rate
Quite a 
lot
Freq- 
uently Severe
Very 
severe
1. Lower abdominal pain O O O O O O O
2. Upper abdominal pain O O O O O O O
3. Heartburn O O O O O O O
4. Regurgitation O O O O O O O
5. Nausea O O O O O O O
6. Vomiting O O O O O O O
7. Loss of appetite O O O O O O O
8. Early satiety O O O O O O O
9. Shortness of breath O O O O O O O
10. Increase of abdominal waist O O O O O O O
11. Involuntary weight loss O O O O O O O
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Supplementary Table 1. Associations of kidney and liver volumes with pain and gastrointestinal 
symptoms (not height-adjusted).
TKV TLV TKLV
R P-val. R P-val. R P-val.
History of pain
Renal related pain 0.10 0.2 0.16 0.006 0.21 <0.001
Liver related pain -0.08 0.2 0.28 <0.001 0.16 0.006
Renal or liver related pain 0.11 0.1 0.20 <0.001 0.26 <0.001
Presence of pain
Renal related pain 0.06 0.3 0.15 0.008 0.19 0.001
Liver related pain 0.00 1.0 0.23 <0.001 0.19 0.001
Renal or liver related pain 0.05 0.4 0.20 <0.001 0.22 <0.001
Severity of present pain 
Renal related pain 0.03 0.6 0.13 0.03 0.16 0.01
Liver related pain 0.02 0.8 0.25 <0.001 0.23 <0.001
Renal or liver related pain 0.02 0.8 0.19 0.001 0.20 0.001
Gastrointestinal symptoms
Lower abdominal pain 0.04 0.5 0.07 0.2 0.07 0.2
Upper abdominal pain 0.02 0.8 0.20 0.001 0.17 0.004
Heartburn 0.1 0.01 0.05 0.4 0.12 0.03
Regurgitation 0.11 0.05 0.13 0.03 0.14 0.01
Nausea -0.06 0.3 0.19 0.001 0.08 0.2
Vomiting -0.02 0.7 0.12 0.04 0.07 0.2
Loss of appetite 0.00 1.0 0.16 0.006 0.13 0.02
Early satiety 0.04 0.5 0.18 0.002 0.17 0.003
Dyspnea 0.04 0.5 0.11 0.05 0.08 0.2
Increasing abdominal volume 0.10 0.1 0.12 0.03 0.20 0.001
Involuntary weight loss -0.03 0.6 0.07 0.2 -0.01 0.9
Severity present gastrointestinal 
symptoms
GI- sum score 0.07 0.2 0.20 0.001 0.20 0.001
Abbreviations are: TKV, total kidney volume; TLV, total liver volume; TKLV, total kidney liver volume; 
GI, gastrointestinal. TKV, TLV and TKLV were log transformed. Denominators depend on the number 
of patients who provided an answer for a specific question in the questionnaire. Renal and liver pain 
measured on scale 1-10 (1= no pain); GI-sum score ranging from 0-100. (0 = no symptoms).
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ABSTRACT
The exposure of clinicians to patients with rare gastrointestinal diseases is limited. This hurts 
clinical studies, which impedes accumulation of scientific knowledge on the natural course, 
treatment outcomes and prognosis in these patients. An excellent method to detect patterns 
on an aggregate level that would not be possible to discover in individual cases, is a registry 
study. This paper aims to describe a template to create a successful international registry for 
rare diseases. We focus mainly on rare hepatic diseases, but lessons from this paper serve 
other fields in medicine, as well. 
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INTRODUCTION
Increasing our knowledge about rare liver disorders, commonly defined as a disorder that 
affects < 1 in 2000 citizens, is imperative. 1 Because most physicians are not exposed to large 
numbers of rare disease patients, their knowledge on the natural course, treatment response 
and prognosis for that rare disease is incomplete. These difficulties clearly limit our under-
standing and are an obstacle for research efforts to improve the outlook of patients with rare 
diseases.
Registries may be the answer to the lack of solid evidence. By definition, a registry is an organ-
ized system that uses observational study methods to collect existing or uniform clinical data 
from individual patients. 2 A registry offers a unique opportunity to conduct research on popu-
lations and conditions that are not generally studied in clinical trials, yet are important to 
clinical decision-makers. 3 
The steps in creating a registry study do not differ much from  the implementation of a clinical 
trial. All the fundamental elements, such as design, study population, timeline and data 
manage ment are likewise present. By contrast, there is no standard guidance as to how to 
design a registry. A helpful open access resource is Registries for Evaluating Patient Outcomes: A 
User’s Guide 2, from the Agency for Healthcare Research and Quality. 
The purpose of this article is to provide a methods-based paper on how to develop an effective 
clinical registry for rare hepatic disorders (Table 1). The most important aspects that are part 
of the decision process are discussed, in view of our own experiences, and highlighted by 
examples from successful rare liver disease registries in literature. As such, the lessons from 
our paper can be applied to other fields in medicine, as well. 
Table 1. A practical guide to develop a clinical registry in 5 steps
1. Define your goal • Define a clear goal: is a registry the right approach for this?
2. Create a network • Identify and include stakeholders
• Keep them updated regularly
• Make the registry transparent 
3. Write your protocol • Define the target population by broad inclusion criteria
• Identify a (small!) core dataset of most relevant data variables
• If possible, include PROMs 
4. Collect high quality data • A web-based datamanagement system is advised as it allows 
decentralized (international) data entry and quality checks
5. Termination of data collection 
and disseminating results
• If a registries has a fixed or open end depends on the purpose
• A feedback loop improves continuous commitment to the 
project and supports dissemination of results
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
56
Chapter 4
Objectives
The most important task before initiating a registry study is to define the main goal. Dividing 
your main goal into specific objectives and outcome measures will help you to decide on the 
best registry design. Registry studies can be created to address a broad spectrum of questions. 
We will illustrate this by using several examples that demonstrate the impact of international 
multicenter databases on clinically relevant issues (Table 2). 
Table 2. Examples of multi-country liver disease registries founded in Europe
Name
Founding 
country 
Participating 
countries Size (~)  Website
Hepatitis delta registry Germany 11 UK http://hepatitis-delta.
org/
DILI registry Spain 1 901 cases
864 patients
http://www.
spanishdili.uma.es/
index.php/es/
Spanish Latin American 
DILI Network
Spain 9 190 cases
181 patients
-
PLD registry the Netherlands 4 > 500 patients - 
European liver 
transplant registry
France/
Germany/U.K.
27 106.849 patients
118.441 LTx
http://www.eltr.org/
International PSC 
Study Group
Norway >17 7.312 patients http://www.ipscsg.org/
Abbreviations: DILI, drug-induced liver disease, EU, European Union; LTx, liver transplantation; PLD, 
polycystic liver disease; PSC, primary sclerosing cholangitis; UK, unknown; U.K., United Kingdom
Natural course, quality of life and epidemiology
One of the goals of a registry could be to study the natural course of disease and associated 
factors. We designed a polycystic liver disease (PLD) registry with exactly this in mind. PLD is a 
disorder where patients progressively develop liver cysts. Information on the natural course of 
PLD, and answers to questions such as what are the predictors of an aggressive disease course 
are lacking, to date. This registry will help us to elucidate the behavioral risk factors for disease 
and assess differences in treatment choices between countries. 4,5 
The UK Primary Biliary Cirrhosis (UK-PBC) collaboration is an excellent example of a network 
that already established a large successful national registry. 6 Primary biliary cirrhosis (PBC) 
is a rare disease (with a prevalence of 30 per 100.000 individuals in the population) with a 
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highly variable phenotype and a high prevalence among women (the male to female ratio is 
1:10). 7 The sheer size of this registry makes it possible to study the clinical profile seen in 
a subgroup of male PBC patients. In addition, this consortium recently developed a UK-PBC 
risk score, to assess prognosis in PBC patients. 6 Finally, this registry enables mapping of the 
natural history of the disease in the total PBC population, to link genetic susceptibility with 
phenotype and outcome, and to study the impact of PBC on the patients’ quality of life. 7,8 On a 
different note, registry studies facilitate studies on incidence and prevalence. A requirement is 
that they sample cases from a confined geographical area. Studies from the Primary Sclerosing 
Cholangitis (PSC) Study Group are a fine example, where al PSC patients in an area of six 
adjacent provinces were identified, comprising 50% of the Dutch population. 9 
Long-term efficacy
In order to study the long-term efficacy of therapeutic interventions, a registry is a perfect tool. 
Indeed, the relative probability of death and graft loss after primary liver transplantation (LTx) 
for a number of rare liver disorders is difficult to estimate. This is the reason for the European 
Liver Transplant Registry, 10 which collects data on death and graft loss as rare outcome 
measures in 8.840 transplanted patients. 
Safety
A patient registry can be used to investigate safety, by collecting data on the unexpected adverse 
events of drugs. Drug-induced liver injury (DILI) is the most cited reason why approved drugs 
are withdrawn from the market by  the US Food and Drug Administration (FDA). 11 Bromfenac 
and troglitazone are two well-known examples of drugs that were withdrawn because of severe 
hepatotoxicity that became apparent in the post-approval period. 12 A specific registry, such 
as the Spanish DILI Registry, collects real-life data of drug safety; and therefore, allows better 
estimation of the magnitude of side effects of a drug,  in terms of incidence or prevalence. 
Cost-effectiveness
Registries are a tool to investigate cost-effectiveness. This has become an important aspect 
of the market access package for novel interventions. The National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER) database has been used to measure compa-
rative treatments and the cost-effectiveness of treatment modalities for hepatocellular 
carcinoma (HCC). This has resulted in a clear picture of the costs of treatment modalities (LTx, 
chemotherapy, radiation, resection or no treatment) over various HCC stages, in relation to 
survival (effectiveness). 13 It goes without saying that registries such as the SEER database can 
be used to address other related questions. 14 
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MATERIAL AND METHODS
Study population 
Target population. 
The purpose of a registry is a key factor that determines the target population. This is the 
population for whom the results are relevant, but at the same time are the source of the registry 
data. The actual population is a mere reflection (and probably a fraction) of the complete 
patient population. Only in case of an extremely rare disease is it possible to reach a coverage 
rate that approaches completeness. For example, the Dutch national Multiple Endocrine 
Neoplasia Type 1 database has been able to capture >90% of the total patient population in 
The Netherlands. 15 This contrasts with the situation in PBC, as the UK-PBC group has managed 
to include approximately 25% of all PBC patients in the UK. 7
In order to appreciate the variability in phenotypic presentation of a disorder such as PLD, it 
is paramount to sample a large number of patients who are followed for a considerable time 
period. We have found it difficult for PLD to have watertight disease definition. A cut-off of the 
number of cysts (as the presence of > 20 liver cysts) is rather arbitrary and is not always strictly 
used by physicians. Some PLD mutation carriers (who most likely will develop the disease 
phenotype, with time) do not have the required number of cysts and may be asymptomatic at 
the time of inclusion. The use of overly strict inclusion criteria enhances the risk of exclusion of 
relevant patient populations, which leads to sampling bias, compromising external validation of 
results. Therefore, it is key to consider the consequences of having too strict inclusion criteria. 
For some diseases, there is a wide variation in terms of disease complexity and the treatment 
strategies between university and general district hospitals. In view of this, the UK-PBC 
consortium managed to include thousands of patients from general centers, as well as 
specialist centers across the entire UK. 7 This resulted in a geographically representative cohort, 
avoiding specialist center bias. A large epidemiological study in PSC patients highlights the 
influence of selection and/or referral bias in population-based studies. The median survival 
until liver transplantation or PSC-related death was 13.2 years in tertiary referral centers, while 
transplant-free survival was 21.3 years in the total cohort (p<0.0001). This highlights that it 
is paramount to collect data from university and general district hospitals, as well as tertiary 
referral centers, for accurate assessment of survival in uncommon diseases such as PSC.9
Design 
International collaboration.
National and international collaboration are crucial, in order to collect a large study population. 
Isolated PLD is a rare liver disease with a prevalence of 1 in 158.000 people, and may also 
occur in the context of autosomal dominant polycystic kidney disease, which carries a 
prevalence of 1 in 1000. 16,17. Currently, our local registry includes approximately 500 patients. 
We used our professional network, established for clinical trials, in order to achieve a larger 
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study population. Promoting your registry online or by presentations supports visibility of the 
project, and enables collaboration with international researchers. 
The global PBC Study Group is a multicenter collaboration between 15 centers that have 
developed a registry, including the medical information of almost 5000 PBC patients in Europe 
and North America, based on individual databases. 18 These data were used to develop a 
validated scoring system to predict transplant-free survival in ursodeoxycholic acid-treated PBC 
patients and to elucidate predictors for development of HCC. 19,20 International successes like 
these emphasize that combining several national databases constitutes a unique opportunity 
to obtain the power to execute studies. 
International cohort studies facilitate our understanding of heterogeneity in rare diseases, 
by stratification of at-risk groups. Risk stratification helps to identify the patient subgroups 
with low and high risk profiles; and allows us to select the patients whom have the greatest 
potential to benefit from treatment. 21,22 The GLOBE-score is a validated risk stratification tool 
that predicts transplant-free survival of PBC patients whom were treated with ursodeoxycholic 
acid, leading to more stratified and evidence-based individualized care. 19
Stakeholders.
In the process of creating a registry, it is pivotal to consider the target audience for whom the 
outcomes matter. The identification of stakeholders is key to help determine the objectives 
of a registry, as they have an essential role in using or disseminating results from a registry. 
Patients, physicians, scientific societies, insurance companies, hospital staff and policymakers 
who may have a vested interest in the development of the registry, should be involved; and 
they are needed for public support. Some key success factors are engagement, i.e. the active 
influence on registry-shaping and long-term commitment. This can be achieved by organizing 
open sessions with different stakeholders, to introduce the concept of a registry in an early 
phase of registry development. In addition, it is important to motivate all parties by making 
the benefits of the registry visible. For example, authorship is important for the visibility of 
individual participants; and it is advisable to set up agreements on authorship, early in the 
process of registry development. 
Data management.
A reliable data management system is essential. Direct communication between electronic 
patient records and registries would be ideal for the collection of registry data, as it saves money 
and time. Since most hospital systems are not yet set up to accommodate this, the most accurate 
and reliable method to collect data is through the creation of a web-based data management 
system. Though costs are higher in comparison to a non-electronic data management system, it 
enhances quality; as validation rules can be formulated that allow monitoring of data integrity. 
The host of a web-based registry can determine which role the data collectors will have in the 
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electronic environment. Every role comes with its own responsibilities. There can be a role for 
patients, in order to complete a questionnaire, or for researchers who collect their medical data. 
Another benefit of a web-based registry is that it allows decentralized data entry; and thus, the 
possibility to collect data internationally. Examples of electronic international registries are the 
Hepatitis C virus-TARGET and the Hepatitis Delta International Network, both of which were 
used for longitudinal observational studies. 23,24 An electronic registry is a financial investment, 
but in view of quality monitoring and efficiency, it will certainly pay off.
Timeline.
Registries can have a fixed or open-end timeline, depending on the overall purpose of the 
registry. Most studies using a registry as observational method have begun as open-ended 
projects, without a pre-defined stopping point. If continuation of the registry does not add any 
valuable information to the already captured data, the registry should be terminated and its 
data reported. 2 
Data collection
Data elements.
Data collection is a time-consuming process; and it is essential to consider all data elements 
that are central to the objective of the registry, to avoid the collection of high volumes of 
data with limited value. What helps in this process is to divide the main goals into specific 
objectives, subdividing further into measurable outcomes. 2 For example, our goal is to study 
the natural and clinical course of PLD, so one important objective is to obtain information on 
the determinants associated with treatment. As such, we need to include at least the following 
elements: current age, gender, age at diagnosis, date of first treatment and treatment strategy. 
We used an expert panel in order to capture all relevant variables. Ultimately, a small number 
of the most important variables remained. 25 
Self-reported data by patients and patient-reported outcome measures.
Collection of variables in patient registries can be performed by patients, researchers or phy-
sicians depending on the origin of data. Another option is to involve patients in this process. 
The UK-PBC group has utilized this concept, as the authors used self-reporting information 
from a large national cohort of PBC patients (n = 2353). For items such as age at diagnosis and 
therapy for PBC, it is recommended to cross-check self-reported data with the medical record 
data; but their results showed a high correlation, suggesting a high level of accuracy of the 
self-reported data. 7
As the patient’s view on their health status and treatment preferences has obtained a central 
position in the choice of treatment strategies, it is desirable to include the patient-reported 
outcome measures (PROMs). PROMs are ideal instruments to measure health gain. 26,27 This 
development is endorsed, as illustrated by the guidance on PROMs that is offered by the US 
FDA. 28 Web-based questionnaires are an ideal modality to collect PROMs. 29
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
61
Creating registries for rare diseases
1
2
3
4
7
Data quality
Data quality and monitoring. 
All elements that are included in a registry should be pre-defined; so that during data collection, 
it is clear to the data collector which information should be entered. For our PLD registry, we 
tested whether all definitions were interpreted in the same manner, by performing a pilot 
study. Two researchers collected data from medical records from the same patients, and the 
results were compared. We were able to clarify obscurities and vague definitions, and include 
some missing questions or variables. In order to verify reliability and reproducibility of data, 
several options are possible. The gold standard for data entry is the double entry of 5-10% 
of all patient points, to check and verify. 30 An even better option is to include a quality and 
control committee, for central and/or local monitoring, in order to guarantee the quality of data. 
Such a committee should monitor electronic data collection and visit different sites for quality 
checks. By formulating validation rules in the electronic data management system, incorrect or 
inconsistent (for instance premenopausal status in men) data can be easily found and rectified. 
Handling missing data.
Registry data that are often routinely collected bear the risk of incompleteness. In order to 
deal with this during data analyses, there are several options. Imputation, a statistical method 
that replaces missing data with substituted values, may be applied here. There are several 
imputation techniques, but multiple imputations that replace missing data by the average of 
the outcomes across multiple imputed data sets, is the most popular. The main advantage of 
multiple imputations is that sample size and variability is preserved. 31 The global PBC studies 
adjusted for missing data by multiple imputations, which did not affect the results. 18,19
Privacy: Anonymous data entry.
Anonymous data entry in research is important, particularly for rare disease registries, as 
the patients may be traced back easily. According to privacy rules, the patient names should 
be substituted by specific codes. We used anonymous codes for all the PLD patients in our 
registry; and separate codes for their country and hospital. In order to trace back patients during 
follow-up, we use decoding lists for every center; including the research number, gender, birth 
date and hospital number. There needs to be caution taken to check the registries for double 
inclusion of patients. This can be performed by checking names; and if needed, data of patients 
with similar birth dates.
CONCLUSIONS
The use of registries in medical science clearly rises up to offer the opportunity to fill in 
important gaps in knowledge about rare diseases, through national and international colla-
boration. This papers provide a framework for the development of a clinical registry and 
includes the important aspects that need attention during this process. 
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ABSTRACT
Polycystic liver disease (PLD) is a rare genetic disorder with progressive cyst growth as the 
primary phenotype. Therapy consists of volume reduction through invasive surgical or 
radiological procedures. To understand the process of treatment decision, our aim was to identify 
factors that increased the likelihood of treatment. We performed a cross-sectional study using 
an international population of patients with PLD. We collected data on the following therapies: 
liver transplantation, resection, fenestration and aspiration sclerotherapy. Data on the potential 
determinants, sex, center, autosomal dominant polycystic kidney disease (ADPKD), autosomal 
dominant polycystic liver disease (ADPLD), age at diagnosis, symptoms and phenotype were 
included. We corrected for follow-up  time. We included 578 patients in our study, and 35% 
underwent invasive therapy. Multivariate regression analysis showed that number of symptoms 
and age at diagnosis of PLD increased the likelihood of treatment (respectively RR:1.4, p<0.001 
and RR:1.4, p=0.03). The choice for liver transplantation or aspiration sclerotherapy was center-
dependent (RR:0.7, p<0.001 and RR:1.1, p=0.03 respectively). The results of our international 
cross-sectional study suggests that a higher number of symptoms and every 10 years of PLD 
diagnosis increases the risk to undergo treatment by 40%. The choice to elect a particular 
modality is center dependent.
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INTRODUCTION
Polycystic liver disease (PLD) is a condition characterized by progressive liver cyst growth. 1 
PLD is part of the phenotype of two genetically distinct disorders. It is present as a primary 
phenotype in autosomal dominant polycystic liver disease (ADPLD), and it is the most common 
extra-renal manifestation in autosomal dominant polycystic kidney disease (ADPKD). 2-4 
Isolated PLD is rare with a prevalence of 1 in 158.000, which contrasts that of ADPKD which has 
a higher prevalence (1: 400-1000 individuals). 5,6 The vast majority of ADPKD patients (94%) > 
35 years-of-age possess hepatic cysts. 4 
Although PLD is often asymptomatic, patients who progress to severe hepatomegaly have 
a decreased health-related quality of life and are often in need of therapy. 7,8 Risk factors 
for progressive disease are age, female sex, estrogen use and pregnancies. 8-10 The concept 
central to PLD therapy is downsizing liver volume as this leads to improvement of symptoms. 3 
Currently, the mainstay of therapies include invasive surgical and radiological procedures such 
as, liver transplantation, the only curative treatment, resection, fenestration and aspiration 
sclerotherapy.2,11 Treatment is indicated in patients who suffer from symptomatic hepatomegaly 
and the choice for a specific therapy mainly depends on the presence and location of dominant 
cysts. 2,3,12 Clear guidelines about timing and choice of therapy are lacking. This might be 
explained by a lack of evidence generated by clinical trials comparing efficacy of invasive 
treatment strategies for PLD. In addition, there are no standardized outcome measures to 
assess treatment success in clinical practice, which hampers the building of an evidence base. 
In order to guide physicians on therapy, it is necessary to explore factors involved in the 
process of treatment decision. To this end, we aimed to delineate patient characteristics and 
disease-specific factors that trigger therapy. Our secondary aim was to identify determinants 
that increased the likelihood of a specific invasive therapy for PLD. 
MATERIALS AND METHODS
Study design and subjects
We performed a cross-sectional study that included PLD patients coming from two independent 
PLD registries. Both registries were developed at two nationwide referral hospitals for PLD, 
Radboud university medical center Nijmegen in the Netherlands (center 1) and University 
Hospital of Leuven in Belgium (center 2). 13 Both hospitals are national referral centers for 
clinical evaluation and treatment of PLD. The Dutch registry contains all PLD patients who 
have visited the outpatient clinic of the Department of Hepatology of the Radboud university 
medical center between January 2008 and February 2015. Patients with ADPKD who had 
visited the Department of Nephrology between January 2008 and December 2014 were 
included, if PLD was present. The Belgium registry includes all PLD patients who had visited the 
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outpatient clinic of the Department of Hepatology of the University Hospital of Leuven, from 
January 2008 to July 2015. According to the Dutch and Belgium regulations, these registries do 
not need formal ethical approval as this was an observational study.
The inclusion criterium for this analysis was a diagnosis of PLD as documented by patients’ 
physician where diagnosis of PLD had literally to be written down in the medical file of 
patients, or as shown on radiological imaging by the presence of ≥20 hepatic cyst larger than 
0.5 cm. Underlying diagnosis of ADPKD or ADPLD was a requirement. ADPKD diagnosis was 
based upon modified Ravine criteria 14, and ADPLD diagnosis was based on the presence of ≥ 
20 liver cysts, in the absence of renal cysts. If renal cysts were present in patients with ADPLD, 
the Ravine criteria should not be met. 15 Patients with hepatic cysts due to other diseases (e.g. 
Caroli’s disease, autosomal resistant polycystic kidney disease) were excluded. 
Potential determinants for treatment
We selected the following patient characteristics and disease-specific factors as potential 
determinants for treatment: sex, age at PLD diagnosis, phenotype, underlying diagnosis of PLD 
(ADPKD or ADPLD), number of symptoms, total liver volume (TLV), height adjusted TLV (hTLV), 
estrogen use and history of pregnancy. Center was also added as a factor determining choice 
of treatment. Parameters that pertained treatment decision were chosen on the basis of expert 
opinion, and evidence coming from studies on risk factors for severe PLD. 5,9,16  
Data collection
Data were retrospectively collected from medical  charts of patients. We included information 
on the following invasive treatment modalities: liver transplantation (combined with or without 
renal transplantation), resection, fenestration and aspiration sclerotherapy. Experimental 
therapies such as somatostatin analogues were excluded since these drugs are mainly used 
in clinical trial settings. We reviewed medical charts for demographics, underlying diagnosis 
of PLD, age at diagnosis of PLD, TLV, hTLV, estrogen use and pregnancies. We used the most 
recent value for TLV that was available. Liver volumes had been calculated in the past by 3D 
measurements of CT scans. This included manually outlining of the liver every 9 mm with 
interpolation of intermediate slices and calculation of TLV. We also collected data on hepatic 
cyst phenotype by assessing MRI, CT, ultrasound images or reviewing imaging reports. We 
have distinguished between a phenotype with either the presence or absence of one or 
more dominant cysts (≥ 8cm). Finally, we collected data on the presence of the following 
symptoms in medical records of patients: abdominal discomfort, feeling full, abdominal pain, 
tiredness, pain in the rib cage and pain in the side. These symptoms were selected as they were 
overrepresented in a Dutch population of symptomatic PLD patients.  17
Statistical analysis
We performed descriptive statistical analyses to summarize population characteristics. Base-
line continuous variables were expressed in mean [standard deviation (SD)] for normally 
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distributed data or median [interquartile range (IQR)] for non-normally distributed data. Dicho-
tomous outcomes were expressed as % (n/n total).
For our primary and secondary aim, we used multivariate logarithmic linked modified Poisson 
regression analysis to generate risk ratios (RRs) for determinants associated with respectively 
treatment and specific treatment modalities. 18,19 Risk ratios >1 and <1 were interpreted as 
respectively, increasing and decreasing the likelihood of treatment or a specific therapy, while 
a risk ratio equal to 1 with a 95% CI smaller than 1 indicates no association We included 
a potential determinant in the regression model only if at least 10 patients (1.7% of 578 
patients) were exposed to the determinant to guarantee adequate statistical power.  For the 
primary analysis, the dependent variable was specified as treatment or no treatment, whereas 
treatment was defined as patients who underwent surgical or radiological therapy, at least 
once. Independent variables included sex, center, age at diagnosis of PLD (defined as age at 
diagnosis of PLD divided by 10 years), phenotype, underlying diagnosis (ADPKD or ADPLD), 
number of symptoms, TLV, hTLV, estrogen use and pregnancy in history. We added the variable 
follow-up, defined as  interval from diagnosis to inclusion in the study divided by 10 years to 
the model in order to correct for follow-up  period.
For our secondary analysis, liver transplantation, resection, fenestration and aspiration sclero-
therapy were included as dependent variables. In this analysis, the same independent variables 
as for the primary analysis were included. Unpaired Student’s t-test or chi-square test were 
used to compare patient- or disease characteristics between specific treatment modalities. In 
addition, a sub-group analysis of hepatic phenotype and treatment strategy between ADPKD 
and ADPLD patients was performed. Finally, we tested whether patients who underwent aspira - 
tion sclerotherapy or fenestration differed on sex, center, age at diagnosis of PLD, phenotype 
and underlying diagnosis of PLD. If patients underwent aspiration sclerotherapy and fene-
stration, the first treatment that was given was used for this analysis. A p-value of <0.05 was 
considered statistical significant. Data were analyzed using SPSS 22.0 (SPSS Statistics, Inc., 
Chicago, IL, USA).
RESULTS
Characterization of the study population
We included 578 patients in our study population and 200 (35%) underwent invasive therapy 
(Fig. 1). The large majority of patients were female (81%) and 383 (66%) had an underlying 
diagnosis of ADPKD (Table 1). A total of 421 patients showed a phenotype without dominant 
cysts while a phenotype with concomitant dominant cysts was present in 54 patients. Liver 
phenotype significantly differed between ADPKD and ADPLD patients (Fig. 2). Patients with 
ADPLD possessed dominant cysts on radiological imaging in 34 patients (22%) whereas this 
was the case in only 21 of ADPKD patients (7%) (p <0.001). 
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Transplantation
(n=77, 13%)
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sclerotherapy
(n=100, 17%)
Fenestration
(n=48, 8%)
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(n= 200, 35%)
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(n= 378, 65%)
Included in registry 
(n= 578)
Figure 1. Overview of the study population. A total of 578 patients were included and 35% (n=200) 
received therapy. A number of patients received ≥ 1 treatment modality.
Figure 2. Liver cyst phenotype in ADPKD and ADPLD patients. (A) A phenotype with dominant cysts (≥ 
8 cm) was significantly more present in ADPLD patients compared to ADPKD patients (22% vs. 7%, p 
<0.001). (B) A phenotype without dominant cysts was more often present in ADPKD  (93% vs. 78%, p 
<0.001).
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Most patients were Dutch (66%, n=380) and stratification of patients by center demonstrated 
that populations from both centers were comparable with respect to sex, TLV and hTLV (Table 
S1). Dutch patients had more symptoms, were more often diagnosed with ADPLD, diagnosed 
at a later age, and more often possessed a phenotype without dominant cysts. The follow-up 
of patients at the university hospital of Leuven in Belgium was significantly longer than the 
follow-up of patients at the Radboudumc in the Netherlands (18 vs. 7 years, p <0.001). There-
fore, all analysis were corrected for follow-up time by including this in the multivariate model.
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Determinants that trigger treatment 
Liver transplantation, resection, fenestration and aspiration sclerotherapy were performed 
in respectively 13%, 1%, 8% and 17% of patients (Fig. 1). Multivariate regression analysis 
re vealed that patients who suffer from more symptoms have a 40% higher likelihood (CI: 
1.17-1.60, p<0.001) to receive treatment (Fig. 3). Every 10 years of diagnosis of PLD was also 
signi ficantly associated with a 40% increased risk of treatment (CI: 1.04-1.88, p=0.03) ). . TLV, 
hTLV, estrogen use and pregnancy in history were not included in the regression analyses as 
data were missing in respectively 56%, 72%, 54% (women only), and 49% (women only) of 
patients.
Table 1. Characteristics of the study population
Complete population  
(n=578)
Female 468 81%
ADPKD 383 66%
Age diagnosis PLD 45 ±13
Center 1 380 66%
Volumetry* 
TLV (mL) 4093 [2717-6066]
hTLV (mL/m) 2639 [1669-3840]
Phenotype*
≥ 20 cysts + ≥1 dominant cyst 54 11%
≥ 20 cysts 421 89%
Symptoms
Abdominal tension 225 39%
Feeling full 210 36%
Abdominal pain 141 24%
Tiredness 129 22%
Pain rib cage 120 21%
Pain side 78 14%
No of symptoms 1 [1-3]
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; hTLV, height adjusted total liver 
volume; PLD, polycystic liver disease; TLV, total liver volume.
Date are in number and percentage (%), mean ±standard deviation, or median and interquartile range [IQR]. 
Center 1= Radboud university medical center Nijmegen, the Netherlands, center 2= University Hospital of 
Leuven, Belgium
*Data were missing in respectively 56%, 72% and 18% of patients for TLV, hTLV and phenotype
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Characterisation of patient undergoing invasive therapy 
Table S3. provides an overview of patient and disease characteristics of individuals who under-
went respectively transplantation, resection, fenestration and aspiration sclerotherapy. Liver 
transplantation was carried out at a median age of 53 ±10 years in a total of 77 patients of 
whom 69 were diagnosed with ADPKD. In 43% (n=33) of patients this was combined with 
a renal transplantation and radiological imaging showed a median TLV of 4271 mL [IQR 
3438-6243 mL] in these patients. Resection was done in 6 patients (1%) and most patients 
underwent other treatment modalities as well. Interestingly, a total of 27 patients received 
>1 different treatment modality. A combination of fenestration and aspiration sclerotherapy 
was most common (9%, n=17). Only a small proportion of the total study population under-
went fenestration (8%, n=48) and a minority of them had ADPKD (38%, n=18). Patients who 
underwent fenestration or aspiration sclerotherapy did not significantly differ on sex, diag-
nosis, age at diagnosis and phenotype (Table S4). We found that the choice for fenestration 
or aspiration sclerotherapy was mainly center dependent (p<0.001). Aspiration sclerotherapy 
was most frequently performed with a total of 197 procedures in 100 patients. Half of patients 
(49%, n=97) had > 1 procedure (range 1-15 procedures), and the majority of patients were 
diagnosed with ADPLD (65%, n=65). 
 
0.6 0.8 1.0 1.2 1.4
Center 
No of symptoms
Follow-up
Aspiration sclerotherapy
0 1 2 3
No of symptoms
Age PLD diagnosis
Follow-up
Treatment overall
0.6 0.8 1.0
Center 
Age PLD diagnosis
Liver transplantation
0.0 0.5 1.0 1.5 2.0
ADPLD diagnosis
Fenestration
Figure 3. Forest plots showing risk ratios with 95% confidence intervals for respectively treatment in 
general, liver transplantation, fenestration and aspiration sclerotherapy. Risk ratios were calculated by 
multivariate regression analyses. A risk ratio of <1 represents a decreased risk and >1 increased risk for 
treatment. A risk ratio of 1 (dotted line) indicates no association. 
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Determinants associated with invasive therapies
We tested the association of six potential determinants with the likelihood to undergo either 
liver transplantation, fenestration or aspiration sclerotherapy (Fig. 3, Table S5). Determinants 
associated with hepatic resection were not analyzed as only seven patients (1%) underwent 
this procedure and a minimum of 10 patients was required. Patients from center 2 had a 
30% higher likelihood (p<0.001) to receive a liver transplantation compared to patients from 
center 1 (Table S5). .The likelihood to undergo a liver transplantation increased by 4% with 
every 10 years of PLD diagnosis (RR 1.035, CI: 1.005-1.065). Multivariate analysis revealed 
that a diagnosis of ADPLD increased the likelihood to undergo fenestration by 30% (p<0.05). 
The number of symptoms was associated with a higher likelihood to undergo aspiration 
sclerotherapy (RR 1.1, p<0.001) . The likelihood to be subjected to aspiration sclerotherapy 
was center dependent (RR 1.1, p=0.03) and increased by follow-up time (RR=1.1, P=0.002).
Therapy differs between patients with ADPKD and ADPLD
We subsequently explored whether treatment strategies differed between patients with 
ADPKD and ADPLD. Fenestration and aspiration sclerotherapy were significantly more often 
performed in patients with ADPLD than in patients with ADPKD (15% vs. 5% and 33% vs. 
9%, both p<0.001) (Fig. 4). By contrast, patients with ADPKD more frequently underwent 
liver transplantation (18% vs. 4%, p<0.001). In a total of 33 patients undergoing liver trans-
plantation, this was combined with a renal transplantation on the same day. 
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Figure 4. Treatment strategies for PLD in autosomal dominant polycystic kidney disease (ADPKD) and 
autosomal dominant polycystic liver disease (ADPLD). Liver transplantation was more often done in 
ADPKD patients whereas fenestration and aspiration sclerotherapy favored ADPLD patients.
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DISCUSSION
The results of our large cross-sectional study demonstrate that number of symptoms and age 
at diagnosis of PLD increased the likelihood to receive treatment for PLD. The choice for either 
liver transplantation or aspiration sclerotherapy was center-dependent. This underscores a 
certain arbitrariness, probably due to a lack of evidence that supports any of the available 
treatment options.
A previous review suggests that the natural course of PLD in ADPLD and ADPKD is similar. 3 
Our study suggests otherwise, and demonstrates that ADPLD patients more often possessed 
large dominant cysts, a phenotype that is amendable to treatment with fenestration or 
aspiration sclerotherapy. 3 The available therapies for patients without dominant cysts, most 
often patients with ADPKD, are resection or liver transplantation. 2,3 A resection is a high risk 
procedure and not often performed in our population. Liver transplantation is a very invasive 
procedure, in particular for a disease that does not lead to liver failure or death. In view of a 
lack of donors, it is not offered widely. 2,3 These reasons probably explain why only 13% of 
this severe PLD population was transplanted while a higher percentage is in need of curative 
therapy. Interestingly, 90% of the transplanted patients were female. This might be explained 
by a more severe disease course in women, probably due to the effect of estrogen. 9  However, 
diagnosis was not significantly associated with any of the invasive therapies. These results are in 
contradiction with a cohort study showing that aspiration sclerotherapy was significantly more 
performed in patients with ADPLD, while patients with ADPKD were more often considered for 
liver transplantation. 20 
About 14% of our treated study population underwent subsequent treatments. The combi-
nation of fenestration and aspiration sclerotherapy was the most frequently chosen option. 
In view of the comparable patients‘ characteristics, our data lend support to center specific 
decision making when it comes to the choice between both treatment modalities. These 
findings indicate that available expertise drives treatment while evidence that singles out the 
best treatment modality is lacking. A randomized controlled trial comparing effectiveness of 
fenestration and aspiration sclerotherapy is necessary to find out which treatment strategy is 
most effective. At the minimum, we should assess treatment outcomes in clinical care of PLD in 
an uniform fashion. Assessment of TLV, symptoms and health-related quality of life before and 
after treatment should become standard of care and collected in a registry to build an evidence 
base of treatment efficacy. 21 In addition, our results demonstrated that liver transplantation 
was more frequently performed in Belgium while in the Netherlands there was a preference 
for aspiration sclerotherapy. Due to a different organ donor policy, Belgium has more donors 
available. This might lower the threshold for physicians to offer transplantation as a treatment 
option. 
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Our study also discovered that a large proportion of patients received treatment (35%), which 
is at odds with literature that indicates that only a small subset of patients is symptomatic. 
2,3,11 Our population consists of patients referred to two nationwide tertiary referral centers, 
which may have contributed to a selection of a population with more severe disease. This may 
overestimate the disease burden of PLD in this population as referral to these centers is often 
triggered by presence of symptoms. The threshold to treat PLD patients is probably lower in 
tertiary centers because of wider experience with PLD and its treatment options. 
The strength of our study was the large, international study population (n=578) in view of the 
rarity of PLD. In addition, both patients with ADPKD and ADPLD were represented in this study 
as well as the most prevalent surgical therapies. Patients from all over the country are referred 
to one of both centers and therefore this study provides a good overview of the clinical profile 
of treated patients in both countries and made it possible to study the effect of center on 
treatment decision.
The main limitation of our study is the cross-sectional design. We were able to investigate 
factors involved in treatment decision, but it is impossible to infer causality. The retrospective 
data collection has led to missing data and therefore liver volume could not be included as 
potential determinant in our prediction model. Assessment of liver volume is time consuming 
and trained staff and software is required. This might explain the amount of missing data for TLV. 
Although, it is questionable whether liver volume plays a major role in the treatment decision 
process as so little volumes were available in the medical charts. Therefore this probably had 
no major impact on the primary outcome. This registry will continue in a prospective fashion 
including more patients worldwide with a long-term follow up. A prospective nature will de-
crease the number of missing data and the long-term  follow-up will support to learn more 
about the prognosis of PLD.
CONCLUSION
The results of our international cross-sectional study suggests that a higher number of symp-
toms and every 10 years of PLD diagnosis increases the likelihood to undergo treatment by 
40%. The choice to elect a particular modality is center dependent. The major implication of 
these findings is that physicians should bear in mind that there is no evidence that favors either 
treatment option, and this contributes to center specific preferences. Therefore, assessing 
effi cacy of therapy by measuring liver volume and symptom burden, are essential to gain 
evidence among the best treatment option. Future studies comparing efficacy of treatment 
modalities would be helpful to fill the gap of knowledge among the best treatment option. 
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SUPPLEMENTARY FILES
Table S1. Characteristics of the study population split for center
Center 1 (n=380) Center 2 (n=198) p
Treatment 121 32% 79 40% 0.05
Sex (% females) 305 80% 163 82% 0.55
Diagnosis (% ADPKD) 230 61% 153 77% <0.001
Age diagnosis PLD 47 ±12 39 ±15 <0.001
TLV (mL) 4324 [2795-6459] 3520 [2543-5292] 0.07
hTLV (mL/m) 2736 [1683-3916] 2163 [1663-3106] 0.32
Phenotype (% ≥ 20 cysts) 296 90% 125 84% 0.04
No of symptoms 2 [0-3] 1 [0-2] <0.001
Follow-up (yrs.) 7 [3-13] 18 [10-32] <0.001
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; hTLV, height-adjusted total liver 
volume; PLD, polycystic liver disease; TLV, total liver volume.
Date are in number and percentage (%), mean ± standard deviation, or median and interquartile range 
[IQR].  
Center 1= Radboud university medical center Nijmegen, the Netherlands, center 2= University Hospital of 
Leuven, Belgium
Table S2. Regression model including potential determinants of treatment 
Multivariate regression analysis
Variables RR (95% CI) p
Female sex 1.8 (0.76-4.28) 0.18
Center 1 vs. 2* -0.6 (0.28-1.30)- 0.20-
Age diagnosis PLD 1.4 (1.04-1.88) 0.03
Phenotype 1 vs. 2** 1.0 (0.36-2.86) 1.0
ADPLD 1.2- (0.17-9.30)- 0.8-
No of symptoms 1.4 (1.17-1.60) <0.001
Follow-up 1.6 (1.11-2.27) 0.01
Abbreviations: ADPLD, autosomal dominant polycystic liver disease; PLD, polycystic liver disease; RR, 
relative risk.
*Center 1= Radboud university medical center Nijmegen, the Netherlands, center 2= University Hospital 
of Leuven, Belgium
**Phenotype 1= ≥ 20 cysts, phenotype 2= ≥ 20 cysts with ≥ 1 dominant cyst
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Table S4. Comparison of patients who underwent aspiration sclerotherapy or fenestration 
Aspiration sclerotherapy
(n=84)
Fenestration
(n=37)
n % n % p
Female sex 72 (86%) 34 (92%) 0.34
ADPLD 53 (63%) 22 (59%) 0.70
Age diagnosis PLD 48 ±14 45 ±12 0.34
Phenotype 1 vs. 2* 60 (71%) 24 (65%) 0.35
Center 1** 82 (98%) 24 (65%) <0.001
Abbreviations: ADPLD, autosomal dominant polycystic liver disease; PLD, polycystic liver disease.
Date are in number and percentage (%) or mean ± standard deviation.
*Phenotype 1= ≥ 20 cysts, phenotype 2= ≥ 20 cysts with ≥ 1 dominant cyst
**Center 1= Radboud university medical center Nijmegen, the Netherlands
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ABSTRACT
Background and aims
A minority of patients with polycystic liver disease suffer from symptomatic hepatomegaly. 
Conventional invasive therapies may cause serious complications and have high recurrence 
rates. Somatostatin analogues can decrease liver volume by diminishing increased intracellular 
cAMP levels in polycystic cholangiocytes, but show modest therapeutic benefit and have 
considerable side effects. The bile acid ursodeoxycholic acid  is an endogenous bile acid and 
FDA-approved for the treatment of primary biliary cirrhosis. Experimental evidence suggests 
that ursodeoxycholic acid reduces cystogenesis in an experimental model of polycystic liver 
disease by restoring diminished intracellular free calcium levels in polycystic cholangiocytes and 
by removing cystic accumulation of cytotoxic bile acids. We hypothesize that ursodeoxycholic 
acid may be effective in reducing total liver volume in polycystic liver disease patients.
Methods
This international, multicenter, randomized, controlled phase II clinical trial evaluates the effect 
of 24 weeks of ursodeoxycholic acid administration as a liver volume reducing treatment for 
polycystic liver disease. Eligible patients are symptomatic polycystic liver disease patients that 
have a total liver volume ≥ 2500 mL. A total of 34 patients will be randomized through a 1:1 
allocation. The intervention group will receive ursodeoxycholic acid 15-20mg/kg/day for 24 
weeks, the control group will receive standard care. Primary outcome is change in total liver 
volume determined by computer tomography volumetry. Secondary outcomes are change 
in symptoms and health-related quality of life measured by questionnaires and change in 
laboratory markers like alkaline phosphatase and -glumatyltransferase. Moreover, safety and 
tolerability of the drug will be assessed.
Discussion
Treatment of polycystic liver disease with ursodeoxycholic acid appears promising based on 
experimental observations. A 4% difference in total liver volume in favor of ursodeoxycholic 
acid treatment versus standard care would indicate comparable efficacy of ursodeoxycholic 
acid to that of somatostatin analogues at lower costs, less side effects and contra-indications 
and a more acceptable route of admission. In case of a positive result, further research should 
focus on the molecular mechanism of action of ursodeoxycholic acid in polycystic liver 
disease, dose-response relationship and combination therapy of somatostatin analogues with 
ursodeoxycholic acid to evaluate synergistic effects.
Trial registration
This trial is registered with ClinicalTrials.gov (identifier: NCT02021110) and EudraCT (identifier: 
2013-003207-19)
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BACKGROUND
Polycystic liver diseases (PLD) are genetic disorders characterized by the formation of multiple 
cysts in the liver derived from the biliary cells (i.e. cholangiocytes). PLD can occur in combination 
with renal cysts as a manifestation of autosomal dominant polycystic kidney disease (ADPKD), 
or without renal cysts as autosomal dominant polycystic liver disease (ADPLD). 1 PLD can lead 
to symptoms such as abdominal pain, dyspnea and early satiety due to the enlarged liver. 
Furthermore physical health-related quality of life (HRQL) is significantly lower in PLD patients 
compared to the general population. 2 The natural course of PLD dictates a growth of 1.8% in 
6-12 months. 1-3 This progressive hepatic cystogenesis in PLD is a consequence of increased 
levels of cAMP and decreased levels of intracellular calcium in cholangiocytes. 4-7 Somatostatin 
analogues decrease cAMP levels and have shown to reduce total liver volume (TLV) with ~5% 
in 6-12 months. 3, 8-10 Although successful to some extent, therapy with somatostatin analogues 
have some inherent disadvantages. A proportion of patients does not respond to somatostatin 
analogues or has side effects such as glucose intolerance, diarrhea or development of gall 
stones. Finally, in most health care systems treatment with somatostatin analogues is very 
expensive. 11 Therefore other options are needed. 
Ursodeoxycholic acid (UDCA) is a hydrophilic endogenous bile acid that is FDA-approved 
for the treatment of several cholestatic disorders such as primary biliary cirrhosis (PBC).12-14 
In vitro studies showed that polycystic human cholangiocyte cultures are characterized by 
decreased [Ca2+] compared to normal human cholangiocytes. UDCA increased intracellular 
calcium and blocked cholangiocyte hyperproliferation in a dose-dependent manner. These 
effects were also observed in cystic cholangiocytes isolated from the PCK rats, an animal 
model that recapitulates human PLD. UDCA treatment for five months inhibited hepatic 
cystogenesis, fibrosis, inflammation, and improved physical status in PCK rats. Moreover, PCK 
rats showed increased intrahepatic concentration of bile acids (particularly within the cystic 
fluid) compared to normal rats. Moreover, the bile that exit the liver of PCK rats presented 
decreased concentration of bile acids compared to normal rats. UDCA treatment decreased the 
concentration of the most cytotoxic bile acids from the liver of PCK rats and normalized the bile 
acid concentration in bile. 15
Based on these results, we hypothesize that chronic UDCA treatment may be an effective 
therapy in reducing TLV, reducing symptoms and increasing HRQL in PLD patients.
Therefore we designed an international, multicenter, randomized controlled phase II clinical 
trial to assess whether UDCA 1 is effective in reducing TLV in symptomatic PLD patients, 2 
improves symptoms and HRQL and 3 is safe and well tolerated. 
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METHODS/DESIGN
Study aim
The primary aim of the CURSOR is to determine whether UDCA is effective in reducing TLV in 
symptomatic PLD patients with liver volumes ≥ 2500 mL. PLD patients suffering from ADPKD 
or ADPLD will receive UDCA 15-20 mg/kg/day for 24 weeks (Appendix A. Fig. 1.). Secondary 
objectives are to determine change in symptoms and HRQL, and change in laboratory values 
like alkaline phosphatase (AP) and -glutamyltransferase (GGT). Finally, safety and tolerability of 
UDCA treatment will be assessed.
Hypothesis
We hypothesize that ursodeoxycholic acid may be effective in reducing total liver volume in 
PLD patients.
Study design and setting
The CURSOR is an international, multicenter, randomized controlled phase II clinical trial in 
PLD patients. Patients will be recruited through 3 specialized centers for PLD; one in Spain 
(Donostia University Hospital, San Sebastian, Spain) and two in the Netherlands (Academic 
Medical Centre Amsterdam and Radboud university medical center, Nijmegen). Trial duration 
will be 40 weeks, consisting of a screening period (4 weeks), treatment period (24 weeks) 
and follow-up (12 weeks). At start and end of treatment we will measure TLV in all patients 
by CT-scanning . Total kidney volume (TKV) in ADPKD patients will be assessed as the natural 
course can be an important factor  and possible confounder within the relation between TLV 
and symptoms or HRQL. In addition, all patients will be evaluated at week 4 and 12 for adverse 
events, drug compliance and lab chemistry. We will complete drug accountability logs and 
record vital signs. Inclusion has started in May 2014 and was completed in February 2015. 
Figure 1. depicts a schematic overview of the trial design.
Randomization and treatment allocation
This trial aims to include 34 PLD patients. Eligible patients will be randomized through a 1:1 
allocation. The intervention group will receive UDCA daily (15-20mg/kg/day), the control group 
will receive standard care. Randomization will be performed using block randomization with 
a block size of four. Patients will be assigned a randomization number which corresponds to a 
treatment arm concealed in a closed envelop. Randomization will be performed by an indepen-
dent researcher.
Study population
Symptomatic PLD patients between 18 and 80 years with underlying diagnosis of ADPLD or 
ADPKD and TLV ≥ 2500mL are eligible for participation to this study. ADPKD diagnosis is based 
upon modified  Ravine16 criteria and PLD is defined as the presence of > 20 liver cysts on CT 
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or MRI scan. TLV has to be judged by the researcher and can be based on clinical findings 
(hepatomegaly), former scans or TLV measurements in the past.
Symptomatic is defined as Eastern Cooperative Oncology Group – Performance Status (ECOG-
PS) ≥ 1 17, and having at least three of the following symptoms:
• Abdominal pain 
• Abdominal distension 
• Abdominal fullness 
• Dyspnea 
• Early satiety 
• Back pain 
• Nausea/vomiting 
• Anorexia 
• Weight loss 
• Jaundice 
The specific study inclusion and exclusion criteria are listed below.
Figure 1. Trial design of the CURSOR trial. All patients are screened for eligibility and the patients who suit 
the criteria are randomized in an equal ratio to either the UDCA arm or the control arm. All patients receive 
a CT scan at baseline and after 24 weeks of treatment. Control visits are performed at week 4, 12 and 24 
after baseline. Follow-up visit will be performed 12 weeks after end of study.
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Inclusion criteria
• 18 ≤ age ≤ 80 years
• PLD, defined as > 20 liver cysts on CT or MRI scan, with underlying diagnosis of ADPLD 
or ADPKD
• TLV ≥ 2500 mL
• Symptomatic defined as ECOG-PS ≥ 1 17, and having at least three out of ten PLD 
symptoms
• Signed informed consent
Exclusion criteria
The following exclusion criteria will be assessed by questioning the patient and assessing 
patient his medical file. 
• Use of oral contraceptives or estrogen supplementation
• Use of UDCA in the three months before baseline
• Females who are pregnant or breast-feeding or patients of reproductive potential not 
employing an effective method of birth control.
• Intervention (aspiration or surgical intervention) within six months before baseline
• Treatment with somatostatin analogues within six months before baseline
• Renal dysfunction (estimated glomerular filtration rate calculated by the
• Modification of Diet in Renal Diseases (MDRD) < 30 ml/min/1.73m2)
• Patients with a kidney transplant
• Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase 
deficiency or glucose-galactose malabsorption
• Acute cholecystitis or frequent biliary colic attacks
• Acute stomach or duodenal ulcers
• Inflammation of small intestine or colon
• Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide 
or cyclosporine 
• Enrolment in another clinical trial of an investigational agent while participating in 
this study
The following exclusion criteria will be judged by the investigator screening  the patient 
for eligibility:
• History or other evidence of severe illness or any other conditions which would make 
the patient, in the opinion of the investigator, unsuitable for the study
• Mental illness that interferes with the patient ability to comply with the protocol
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Trial treatment
The intervention group will receive an oral dosage of 15-20 mg/kg/day UDCA in 2 doses 
(morning and evening) for 24 weeks. UDCA is a non-toxic, endogenous, hydrophilic bile acid 
which affords protection against hydrophobic bile acids. UDCA is well accepted in clinical 
practice, physicians have experience with the drug for more than 30 years. For example, oral 
UDCA administration is safe and the only effective therapy approved by the FDA (13-15 mg/
kg bodyweight per day) for PBC. 18 The mechanism of UDCA seems to be dose-dependent in 
PBC and therefore the highest acceptable dose is preferred to achieve the maximum effect. 
19 This accords with in-vitro data that documented a dose dependent inhibition of UDCA on 
the hyperproliferation of polycystic human cholangiocytes. Moreover, doses of 25 mg/kg/day 
for 5 months showed therapeutic benefits in PCK rats. 15 As a result patients will receive a 
UDCA dose of 15-20mg/kg/day. The most common (1-10%) side effects are diarrhea and sticky 
stools. 20 In case of dose related side effects down titration will be accomplished by reducing 
the amount of pills, one pill at a time.
Study endpoints
Primary outcome
The primary objective of the CURSOR trial is to assess the proportional change in TLV from 
baseline to week 24.
Secondary outcomes
Secondary outcomes are as follows:
• Absolute change in TLV and TKV from baseline to week 24 
• Proportion of patients having any reduction in TLV
• Proportional change in TKV from baseline to week 24
• Change in symptoms measured by the gastro-intestinal questionnaire (GI-Q) 21 PLD-
questionnaire (PLD-Q), and EORTC QLQ-C30 at baseline, end of treatment and follow-
up. 
• Change in HRQL as measured by the Medical Outcomes Study 36-item Short-Form 
Health Survey (SF-36) and visual-analogue scale (VAS) score of the European Quality of 
Life-5 dimension ( EQ5D) at baseline, end of treatment and follow-up. 
• Change in laboratory markers like GGT and ALP at baseline, end of treatment and 
follow-up.
• Evaluation of safety and tolerability by documenting (serious) adverse events
Data collection
All data will be collected by a case record form designed to capture all visit information 
including medical history, medication use and adverse events. The duration of the trial will be 
40 weeks for all patients. Screening will be completed in week -4 to 0, in the second phase 
patients are either treated with UDCA or receive standard care for 24 weeks. During this phase 
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patients will visit the hospital at baseline (week 0), week 4, 12 and 24 (end of treatment). 
Follow-up visit will be at week 36, 12 weeks after end of treatment. Medical history, medication 
use, adverse events, tolerability and drug accountability will be assessed during each visit. 
Furthermore vital signs, upper arm circumference and weight are measured. In addition blood 
samples will be drawn. The two main study visits at week 0 and 24 include a CT-scan and 5 
questionnaires. At follow-up, the 5 questionnaires will be completed as well.
Study procedures
This study consist of six visits including screening visit, 3 treatment visits (week 4, 12, 24)  and 
one follow-up visit (week 36). The requested parameters at the different visits are listed below. 
Screening
• Written informed consent
• Eligibility criteria check
• Assessment of ECOG-PS score 17 
• Verification of the diagnosis of PLD
• Medical history and concomitant medication
• Physical examination and vital signs
• Upper arm circumference
• Laboratory chemistry: liver function tests (INR, albumin), liver enzymes (AST, ALT, total 
bilirubin, direct bilirubin, GGT, ALP, kidney function (MDRD)
Every visit
• Vital signs 
• Weight
• Upper arm circumference
• Lab chemistry: Liver enzymes, kidney function, albumin 
• Adverse events
• Concomitant medication
• Drug accountability
Baseline (week 0)
• Serum storage for future reference (6 ml)
• Questionnaires
• GI-Q
• SF-36 questionnaire
• PLD-Q
• EORTC QLQ-C30 
• VAS score- EQ5D
• CT scan of liver and kidneys
• Randomization and treatment allocation to UDCA or standard treatment
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End of treatment (week 24)
• Serum storage for future reference (6 ml)
• Questionnaires
• GI-Q 
• SF-36 questionnaire 
• PLD-Q
• EORTC QLQ-C30 
• VAS score- EQ5D
• CT scan of liver and kidneys
Follow-up visit (week 36)
• Serum storage for future reference (6 ml)
• Questionnaires
• GI-Q
• SF-36 questionnaire
• PLD-Q
• EORTC QLQ-C30 
• VAS score- EQ5D
CT Scanning and 3-Dimensional Volumetry
CT scans at baseline and week 24 will be performed without contrast on a multidetector CT 
scanner (Somatom Sensation 64; Siemens Medical Solution AG, Erlangen, Germany). All CT 
scans are blinded to patient identity and date of birth as well as date of scan. TLV and TKV 
will be calculated by 3D measurement of CT scan slices using Pinnacle3 ® version 8.0 g 
(Philips, Eindhoven, The Netherlands). Imaging protocol includes that CT scans will have a slice 
thickness of 3 mm. Liver and separate kidneys will be outlined manually every 9 mm. The 
software interpolates the intermediate slices and calculates the areas within the indicated 
circumference, and finally, TLV and TKV. All CT scans will be measured by 2 researchers, TLV 
will be determined by using the average of both measurements. Inter-observer variation will 
be calculated. Unblinding of CT scans will be performed after measurement of volumes of all 
patients.
Patient reported outcome measures
During the CURSOR study patients will complete the GI-Q, the PLD-Q and the EORTC QLQ-C30 
in order to assess symptoms. The GI-Q contains 11 questions about symptoms that patient have 
suffered from over the past four weeks using a 7-point Likert scale, ranging from 0 (“none”) to 
6 (“severe”). The PLD-Q is a recently developed questionnaire specific for PLD patients and 
contains 16 questions (PLD-Q, Radboud University Medical Center, Nijmegen, the Netherlands). 
As the PLD-Q has not been validated yet, the EORTC QLQ-C30, a validated questionnaire has 
been included in the CURSOR as well. This questionnaire includes 13 symptoms which can be 
scored from 1 (“not at all”) to 4 (“very much”). 22
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Change in HRQL will be assessed by the SF-36 and VAS score-EQ5D. The SF-36 is a 36-questions 
instrument consisting of eight scales of health assessing functional health and well-being. 
These scales have been clustered into a physical component summary score (PCS), and a 
mental component summary score (MSC) and have been validated in a variety of studies for 
multiple chronic illnesses. 23 
The VAS score-EQ5D records the patient’s self-rated health on a vertical, visual analogue scale 
where the endpoints are labeled “best imaginable health state” (“100”) and “worst imaginable 
health state” (“0”). 
Laboratory values
Several laboratory values will be measured during the study timeline for safety measures. 
Abnormalities in levels of the liver enzymes AST and ALT in PLD patients are generally absent. 
However, serum levels of ALP and GGT are often raised in patients suffering from severe hepa-
tomegaly due to PLD. 24 As UDCA seems to reduce these levels shown in former trials in PBC 
patients, secondary endpoint is to analyze the effect of UDCA on ALP and GGT compared to the 
control group. 25, 26
Study withdrawal
All subjects have the right to withdraw from the study at any time during the trial. Patients will 
be withdrawn from the study for any of the following reasons: withdrawal of informed con-
sent, pregnancy, failure to adherence to protocol requirements, study drug discontinuation, 
surgical intervention on the liver during the trial and if the investigators conclude that it is 
in the patient’s best interest for any reason. Replacement after study withdrawal will only be 
allowed if withdrawal occurs between screening and baseline.
Sample size considerations
We think that in order for UDCA to be an effective therapy, it needs to be at least equally 
effective as somatostatin analogues. A recent trial showed a 4% difference in means in TLV 
between the somatostatin and placebo group. 3 A sample size of 30 will achieve 80% power to 
detect a difference of 4% in liver volume using a two-sided a-level of 0.05. Taken into account 
a dropout rate of 10%, the minimal sample size needs to be 34 patients with 17 patients in 
each group.
Statistical analysis
Intention-to-treat (ITT) analyses will be used for all clinical outcome variables. The ITT popu-
lation includes all patients who received at least one dose of the study drug. 
The effect of UDCA will be assessed by determining the proportional change between baseline 
and final CT-scan between the two groups. TLV will be determined as indicated before. Con-
tinuous variables will be expressed in mean ± SD if normally distributed, otherwise as median 
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± interquartile range. All secondary outcomes will be compared between both arms using t 
test for normally distributed data and the Mann-Whitney U for non normally distributed data. 
Symptom scores of the EORTC 
and HRQL measured by the SF-36 and VAS-score EQ5D, will be compared between both 
treatment arms and calculated by using the appropriate scorings manuals. 22, 23, 27 Change in 
symptom severity as measured by the GI-Q will be calculated by using a sum score of upper 
gastro-intestinal symptoms severity ranging from 0 to 66. 21, 28 
All adverse events occurring during the study will be recorded in the patient’s medical records. 
The incidence of events considered to be at least possibly related to the study treatment will 
be summarized by treatment group and severity. 
All statistical analyses will be two-sided with a critical significance level of 5%. Analyses will 
be performed using SPSS software version 20.0 (Chicago,IL,USA).
Ethical considerations
Ethical approval has been obtained from the Central Committee on Research Involving Human 
Subjects and by the local accredited Medical Research Ethics Committee of the region Arnhem-
Nijmegen, the Netherlands (reference number: 2013-371) . This study will be performed in 
accordance with the protocol, the guidelines of Good Clinical Practice/ ICH, the principles of 
the Declaration of Helsinki 1964 as modified by the 52nd WMA General Assembly, Edinburgh, 
Scotland, October 2000 including two notes of clarification paragraph 29 and 30, and the local 
national laws governing the conduct of clinical research studies.
Safety of trial subjects is monitored by an independent data safety monitoring board (DSMB).
DISCUSSION
The CURSOR trial is designed to determine whether treatment with UDCA may result in a 
reduction of TLV in symptomatic PLD patients. Furthermore the effect on symptoms and quality 
of life will be studied. There is a need for medical options that curtail PLD growth and thereby 
reduces symptoms. A novel therapy should have an excellent safety/efficacy balance while 
being cost-effective. Current therapies such as liver transplantation are effective but carry 
a high mortality risk, and in view of shortage of liver-donors is an option that is not readily 
available. 1 Somatostatin therapy is a promising option, but is expensive, its efficacy is not 
universal, and side effects after prolonged administration such as hyperglycemia, bradycardia 
and development of gallstones can be obstacles for widespread use. Alternative options are 
therefore urgently needed. 
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Ideally, a drug that is effective in PLD meets with several requirements. The drug should possess 
a large treatment effect that is able to reverse the natural course of the disease. The effect 
should not only diminish TLV but also improve a wide spectrum of domains that compose the 
quality of life. The effect should be quickly visible, predictable and universal. Likewise the 
drug should be cheap and widely available and come in an oral administration form. Lastly, 
a finite short therapy course should be enough to result in a long-lasting effect. UDCA meets 
with some of the requirements and there is a solid biological plausibility that supports its use 
in PLD. 
Cystogenesis in PLD is associated with increased cAMP and decreased calcium levels. 5, 6, 29 
Theoretically reversal of raised intracellular cAMP and decreased calcium levels might be an 
effective approach to reduce polycystic liver volume. UDCA is registered and used in several 
cholestatic disorders such as PBC and intrahepatic cholestasis during pregnancy. 13, 14, 30, 31 
Placebo-controlled trials support the anticholestatic efficacy of UDCA in PBC. Biomarkers such 
as GGT and ALP markedly decrease in UDCA treated PBC patients. Interestingly, elevations 
of GGT (51%) and ALP (17%) are frequently observed in severe PLD. 32 Probably elevations 
of GGT and ALP reflect increased cholangiocyte activity and curtailing or even reversing this 
process might be beneficial in PLD. 
To this end we designed a clinical trial that is powered to detect a significant change in polycystic 
liver volume in PLD patients treated with UDCA. In addition we will evaluate symptoms and 
HRQL after 24 weeks of therapy, as well as changes in biomarkers such as GGT and ALP. Finally, 
we aim to study safety and tolerability of UDCA.
The strength of this trial is that we will include patients with a more severe phenotype such 
as those with symptoms and grossly enlarged livers (threshold ≥ 2500mL). This is the patient 
population that is in need of therapy as HRQL is reduced in these patients. 2 Furthermore 
the international character of this trial makes it possible to generalize findings to a larger 
population of patients. If UDCA treatment would lead to a >4% difference in change in TLV 
relative compared to no treatment this would suggest UDCA to be equal or even superior to 
the effect of somatostatin analogues. 
There are some limitations that are worth mentioning. First, it would be most desirable to 
have a formal placebo controlled design to include placebo effects, especially when assessing 
symptom reduction and HRQL improvement. However, our primary aim (reduction in TLV) is an 
objective measure that cannot be influenced by patients, hence the reason to obviate placebo. 
Secondly, ADPKD patients with MDRD <30 ml/min/1.73m2 will be excluded from the trial, as 
UDCA has never been studied in this patient group. Therefore the results of this study cannot 
be generalized to this specific subgroup of ADPKD patients with symptomatic PLD. 
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In conclusion, by designing the CURSOR trial we hypothesize that UDCA therapy in symptomatic 
PLD patients reduces TLV, reduces symptoms and improves HRQL. 
Intentionally we have chosen to first explore effect of UDCA monotherapy, in order to prevent 
influence of other therapies. Combining UDCA with for example somatostatin analogues could 
hypothetically result in a synergistic effect. This should, as well as dose-response relationship 
and the molecular mechanism of action of UDCA in PLD be studied in a next trial. 
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ABSTRACT 
Background and aims
Ursodeoxycholic acid (UDCA) inhibits proliferation of polycystic human cholangiocytes in vitro 
and hepatic cystogenesis in a rat model of polycystic liver disease (PLD) in vivo. Our aim was to 
test whether UDCA may beneficially affect liver volume in patients with advanced PLD. 
Methods
We conducted an international, multicenter, randomized controlled trial in symptomatic PLD 
patients from three tertiary referral centers. Patients with PLD and total liver volume (TLV) ≥ 
2500 ml were randomly assigned to UDCA treatment (15-20mg/kg/day) for 24 weeks, or to 
no treatment. Primary endpoint was proportional change in TLV. Secondary endpoints were 
change in symptoms and health-related quality of life. We performed a post-hoc analysis of the 
effect of UDCA on liver cyst volume (LCV). 
Results
We included 34 patients and were able to assess primary endpoint in 32 patients, 16 with 
autosomal dominant polycystic kidney disease (ADPKD) and 16 with autosomal dominant 
polycystic liver disease (ADPLD). Proportional TLV increased by 4.6 ± 7.7% (mean TLV increased 
from 6697 ml to 6954 ml) after 24 weeks of UDCA treatment compared to 3.1 ± 3.8% (mean TLV 
increased from 5512 ml to 5724 ml) in the control group (p=0.493). LCV was not different after 
24 weeks between controls and UDCA treated patients (p=0.848). However, UDCA inhibited 
LCV growth in ADPKD patients compared to ADPKD controls (p=0.049). 
Conclusions
UDCA administration for 24 weeks did not reduce TLV in advanced PLD, but UDCA reduced LCV 
growth in ADPKD patients. Future studies might explore whether ADPKD and ADPLD patients 
respond differently to UDCA treatment.
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INTRODUCTION
Polycystic liver diseases (PLDs) are genetic disorders that lead to the formation of cysts 
through out the liver. 1 PLD is present in a large proportion of patients with autosomal dominant 
polycystic kidney disease (ADPKD), a disorder where the majority of patients (94%) develop 
hepatic cysts in addition to kidney cysts. 2 Multiple hepatic cysts can also appear in patients 
without renal involvement (i.e., autosomal dominant polycystic liver disease (ADPLD)). Due 
to progressive cyst growth, patients can develop hepatomegaly. This could lead to symptoms 
such as abdominal pain, early satiety and an impaired health-related quality of life (HRQL). 1, 
3, 4 Current therapies for PLD such as fenestration and liver transplantation are invasive with 
high risk of complications. 5 Medical treatment with somatostatin analogues does hold some 
promise and is able to reach a total liver volume (TLV) reduction of ~5% in 6-12 months. 6-8 
However, not all patients do respond and some may develop side effects such as glucose 
intolerance, diarrhea or gallstones. Moreover, somatostatin analogues are very expensive. 
Therefore, other options are needed. 
The genetic profile of ADPKD and ADPLD is distinct but the resulting liver phenotype is 
similar.1 ADPKD is mainly caused by mutations in the polycystic kidney disease 1 gene (PKD1) 
or PKD2 gene, while ~25% of ADPLD cases have a mutation in one of the three known genes 
PRKCSH, SEC63 or LRP5. 9 The PKD genes encode for polycystin 1 and 2 respectively, both 
integral membrane proteins acting as a Ca2+ permeable receptor channel complex. 10 Muta-
tions in polycystins result in decreased intracellular calcium levels (Ca2+i) and subsequent 
increased intracellular cyclic adenosine monophosphate (cAMP) levels 10, 11. This promotes 
the hyperproliferation of cystic cholangiocytes and is a crucial step in hepatic cyst formation 
that might serve as a potential target for novel pharmacological therapy. 10-13 In this regard, 
previous studies have shown that cholangiocytes from PCK rats, an animal model with PLD 
resembling human PLD, have increased intracellular cAMP levels and diminished Ca2+I levels 
compared to normal human cholangiocytes. Experimental restoration of the Ca2+I levels with 
a calcium ionophore inhibited cAMP-mediated hyperproliferation of PCK rat cholangiocytes. 11 
Thus, strategies aimed to normalize the reduced Ca2+i levels in polycystic cholangiocytes are 
considered of potential therapeutic value. 10 
The hydrophilic bile acid, ursodeoxycholic acid (UDCA), is a well-known Ca2+ agonist in hepato-
cytes 14 and cholangiocytes 15. We recently demonstrated that UDCA restores dimi nished Ca2+I 
levels in polycystic human cholangiocytes in culture and decreases hepatic cysto genesis in 
PCK rats after 5 months of treatment. 16, 17 This beneficial effect of UDCA was also associated 
with downregulation of the high concentration of cytotoxic bile acids found in PCK rat livers. 
17 UDCA is safe and well tolerated in the treatment of patients with primary biliary cholangitis 
and gallstone disease. 18
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We hypothesized that 6 months of UDCA treatment leads to reduction in liver volume, symptoms 
and improvement of HRQL in PLD. Therefore, we designed an international, multicenter, 
randomized controlled phase 2 trial with proportional change in TLV as the primary endpoint. 
MATERIAL AND METHODS
Study population 
We included symptomatic PLD patients between 18 and 80 years with an underlying diagnosis 
of ADPLD or ADPKD, and a TLV ≥ 2500 ml. PLD was defined as the presence of ≥ 20 liver 
cysts on computed tomography (CT) or magnetic resonance imaging (MRI) scan, and ADPKD 
diagnosis was based upon modified Ravine criteria. 19 Liver volume was judged by one of the 
investigators and based on clinical findings (symptoms and physical examination), imaging or 
former TLV assessments. Symptomatic PLD was defined as an Eastern cooperative oncology 
group – performance status of ≥ 1 and the appearance of at least three of the following 
symptoms: abdominal pain, abdominal distension, abdominal fullness, dyspnea, early satiety, 
back pain, nausea/vomiting, anorexia, weight loss and jaundice. 20 Full details of inclusion and 
exclusion criteria are shown in Supplementary material and methods. 
This trial was conducted at three university centers specialized in PLD: one in Spain (Donostia 
University Hospital, San Sebastián, Spain) and two in the Netherlands (Academic Medical 
Center Amsterdam and Radboud university medical center, Nijmegen). 
Trial design and treatment allocation
Eligible patients were randomly assigned in blocks of four in a 1:1 ratio to receive UDCA 
(Ursochol, Zambon, the Netherlands), orally twice a day, in a dose of 15-20mg/kg/day for 24 
weeks, or to undergo follow-up without any clinical trial treatment. Sequence generation was 
handled by an independent researcher using www.randomization.com. To ensure allocation 
concealment, all randomization numbers were placed in opaque, sealed envelopes bundled 
per four. Envelopes were opened by an independent researcher one day before baseline in 
order to prepare medication. The independent researcher passed details of group allocation 
on to the clinical researcher of each center.
UDCA was provided by the local pharmacy of every center. Treatment was initiated the day 
after baseline visit. Compliance with medication was assessed at week 24 by pill count. During 
the trial, patients were not allowed to undergo interventions such as aspiration sclerotherapy 
or surgery, or to use somatostatin analogues. 
Study procedures 
A 36-week follow-up period was planned, in which a total of five visits at the outpatient clinic 
were scheduled: week 0 (baseline), 4, 12, 24 (end of treatment) and 36 (follow-up) (Fig. 1). 
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For safety measures, aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), 
bilirubin (direct and total), gamma-glumatyltransferase (GGT), alkaline phosphatase (AP), crea-
tinine and international normalized ratio (screening only) were assessed during all visits and 
adverse events were recorded. At week 0 and 24 CT scans without contrast were performed on 
a multidetector CT scanner . CT scans had a slice thickness of 3 mm.
For analysis of the primary outcome, all CT scans were blinded to patient identity, treatment 
allocation and date of scan. Scans were measured in random order. TLV and total kidney volume 
(TKV) were calculated by 3D measurement of CT scan slices using Pinnacle3® version 9.6 g 
(Philips Healthcare in Fitchburg, WI, USA). 21 Liver and kidneys were outlined manually every 
9 mm. Software interpolated intermediate slices and calculated areas within the indicated 
circumference, and finally, TLV and TKV were determined. To test whether TLV measurements 
were reliable, a random set of 18 CT scans (9 baseline and 9 week 24) were measured by two 
researchers (HD & MN) and inter-observer variation was assessed using a Bland-Altman plot. 
Bland-Altman plot showed a mean difference of -0.2 ± 2% between the two researchers. TLVs 
from one researcher (HD) were used for analysis of primary outcome.
Liver cyst volume (LCV) was measured blindly, by fully automatic segmentation of liver images 
using an image processing pipeline built in MeVisLab (version 2.7.1, MeVis Medical Solutions 
AG, Bremen, Germany) inspired by Ruggenenti. 22 Parameters for automatic segmentation were 
maintained constant for all patients to prevent variability between measurements. Images were 
initially smoothed by an anisotropic diffusion filter, using the modified curvature diffusion 
equation (time step 0.0625, conductance parameter 3, number of iterations 15). 23 This filter 
reduces image noise without compromising edges or other important details in the image. 
Subsequently, images were marked with the TLV segmentation exported from Pinnacle (border 
voxelized at midpoint, in order to reproduce pinnacle TLV values), and Otsu thresholding (512 
Figure 1. Trial design of the CURSOR trial. Patients were screened for eligibility and eligible patients 
were randomized in an equal ratio to either the UDCA group or the control group. All patients received a 
CT scan at baseline and 24 weeks. Control visits were performed at week 4, 12 and 24 after baseline. A 
follow-up visit was performed 12 weeks after end of study (week 36).
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bins) was performed to divide the liver into two classes 24: cystic volume and parenchyma, 
based on the image histogram. TLV and LCV were calculated from these segmentations.
Endpoints
Primary outcome of this trial was proportional change in TLV from baseline to week 24 between 
UDCA group and control group. Secondary endpoints were: change from baseline to 24 weeks 
in (i) absolute and height-adjusted TLV (hTLV), (ii) absolute and height-adjusted total kidney 
volume (hTKV), (iii) symptoms, and (iv) HRQL. In addition, safety and tolerability were evaluated. 
Analysis of LCV as a secondary outcome parameter was added to the protocol after the trial had 
started in order to relate our findings to the results in PCK rats treated with UDCA. 17 
Symptoms were assessed using the PLD questionnaire (PLD-Q) and gastrointestinal-question-
naire (GI-Q). The PLD-Q is a recently developed and validated questionnaire for PLD patients 
that includes 13 items about frequency and discomfort of PLD-specific symptoms such as early 
satiety and abdominal pain. 25 The GI-Q includes 11 items related to abdominal symptoms. 26, 27 
Generic HRQL was measured by the medical outcomes study 36-Item short-form health survey 
(SF-36) and the European organization for research and treatment of cancer quality of life 
questionnaire core-30 (EORTC). The SF-36 consists of eight scales resulting in a norm-based 
summarizing physical (PCS) and mental component score (MCS). The EORTC is a validated 
questionnaire that includes nine symptom scales. Finally, we measured overall HRQL using the 
visual-analogue scale score of the European quality of life-5 dimension (VAS-EQ5D). Scoring 
manuals were used to calculate scores and to handle missing items. 
Sample size and statistical analysis
A change in TLV of 4% in favor of UDCA compared to no treatment was assumed to be clinically 
relevant, based on previous trials with somatostatin analogues. 28 A priori sample size calcu-
lation revealed a sample size of minimum 34 patients for a statistical power of 80%, a type I 
error of 0.05 using a two-tailed test, a standard deviation of 4% and a dropout rate of 10%. 
Clinical outcome variables were analysed on a modified intention-to-treat basis defined as all 
randomly assigned patients. No interim analyses were done. 
Continuous variables were expressed as mean (95% confidence interval (CI)) if normally 
distributed, otherwise as median (interquartile range (IQR)). Primary outcome and secondary 
outcomes on TLV, TKV, HRQL and symptoms, were tested with independent t-tests between 
groups and paired sampled t-tests comparing baseline and end of study within groups. 
There were no methods used to correct for missing outcomes in the analyses of primary and 
secondary endpoints. Adverse and serious adverse events were counted per group and patient. 
Most frequent adverse events and all serious adverse events were reported. A chi-squared 
test was used to compare numbers of episodes of adverse events between the control and 
UDCA group. In order to assess differences in response to UDCA, post-hoc subgroup analyses of 
ADPKD and ADPLD patients’ outcomes were performed for primary and secondary outcomes. 
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All p values calculated were two-tailed, and a p value< 0.05 was considered statistically sig-
nificant. Analyses were performed using SPSS 22.0 (SPSS Statistics, Inc., Chicago, IL, U.S.A).
Ethical consideration and registration
Ethical approval for the two Dutch centers was obtained from the local institutional review 
board, i.e. the committee human research region Arnhem-Nijmegen (CMO Arnhem-Nijmegen). 
For the Spanish center, ethical approval was obtained from the ethics committee for clinical 
research (CEIC-Euskadi). The study was performed in accordance with the guidelines of Good 
Clinical Practice/ ICH and the principles of the Declaration of Helsinki. Every patient signed 
informed consent. Safety of trial subjects was monitored by an independent data safety moni-
toring board. This trial is registered at https://www.clinicaltrialsregister.eu/, EudraCT Number: 
2013-003207-19, and at https://www.clinicaltrials.gov/, identifier: NCT02021110.
RESULTS
Study population
From May 2014 through February 2015, 38 patients were screened for eligibility and 34 
patients were randomized. A flow chart of the study population is shown in Fig. 2. All patients 
completed the total follow-up of 36 weeks by November 2015. Imaging analysis revealed that 
one patient (UDCA group) did not meet the inclusion criterion TLV ≥ 2500 mL; this patients 
was excluded from further analyses. Another patient was excluded from analysis of primary 
outcome only, as baseline CT scan was missing (UDCA group). In total 32 patients were analyzed 
for primary outcome and 33 for secondary outcomes. Median age was 53 years [IQR: 42-58 
years] in the UDCA group and 48 years [IQR: 43-53 years] in the control group (Table 1). In the 
control group 7 patients (40%) had ADPKD, compared to 9 patients (60%) in the UDCA group. 
Mean hTLV was 3207 ml/m (95% CI: 2627-3786 ml/m) and 3940 ml/m (95% CI: 2722-5157) 
ml/m in the control and UDCA group, respectively. 
Mean dose of UDCA in the intervention group was 19.9 ± 0.7 mg/kg/day. Compliance, assessed 
by the average number of pills taken, was 97.0 ± 3.0%. There were no dose reductions or drug 
discontinuations during the trial.
Liver volume
The proportional change in TLV from baseline to 24 weeks between both arms was not 
significantly different (UDCA group: 4.6% vs. control group: 3.1%, p = 0.493) (Fig. 3). Mean TLV 
increased from 6697 ml (95% CI: 4605-8788 ml) at baseline to 6954 ml (95% CI: 4781-9127 
ml) at week 24 in the UDCA group, indicating a mean relative increase of 4.6% (95% CI: 0.3%-
8.8%) (Table 2). TLV in the control group increased from 5512 mL (95% CI: 4445-6579 mL) to 
5724 mL (95% CI: 4548-6900 mL), a mean relative increase of 3.1% (95% CI: 1.1%-5.1%). 
Individual changes in TLV for both groups showed that TLV decreased in 3 patients treated with 
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Figure 2. Flow chart of the CURSOR trial. Of the 38 patients assessed for eligibility, 34 were found 
eligible and were included in the trial. A total of 17 patients were assigned to UDCA and 17 patients to 
no treatment. Two patients were excluded from analysis of the primary outcome, both randomized to the 
UDCA group.
Figure 3. Percentage change in TLV after 24 weeks. TLV increased with 3.1% in the control group vs. 4.6% 
in the UDCA group. This change was not significantly different (p = 0.493).
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UDCA and in 3 patients in the control arm (Fig. 4). One patient (UDCA group), diagnosed with 
ADPLD, had an extreme increase in TLV of 30%. A sensitivity analysis of primary endpoint in 
which this patient was excluded, did not change results. There was no significant change in 
proportional TLV from baseline to week 24 between UDCA and control group in a subgroup 
analysis of ADPKD and ADPLD patients (respectively p=0.267 and p=0.210).
In addition, there was no statistically significant difference in hTLV after 24 weeks between 
UDCA group (152 ml/m, 95% CI:32-272 ml/m) and control group (121 ml/m 95% CI:41-
201 ml/m) (p = 0.642). Notably, in a subgroup analysis of ADPKD patients, hTLV significantly 
increased in the control group (172 ml/m, 95% CI:54-302, p = 0.018) compared to a non-
significant increase in the UDCA group (152 ml/m, 95% CI:-16 -319, p = 0.071) this increase 
was not statistically different between both groups (p = 0.835). In ADPLD patients, hTLV did not 
change within and between UDCA and control group respectively (85 ml/m, 95% CI:-31-202 
ml/m vs. 153 ml/m, 95% CI -92-398 ml/m, p = 0.507). 
Table 1. Baseline demographics and clinical characteristics 
Control group
 (n=17)
UDCA group 
(n=15)
Demographics
Age (years)a 48 [43;53] 53 [42;58]
Sex (female)a 16 (94%) 12 (80%)
Diagnosis  
ADPKD 7 (41%) 9 (60%)
ADPLD 10 (59%) 6 (40%)
Age at diagnosisa 38 [34;42] 43 [36;50]
Years of diagnosis 11 (8;14) 9 (6;12)
Vital statistics
Weight (kg) 78 (72;85) 81 (74;88)
BMI (kg/m2) a 27 [25;29] 28 [26;30]
Imaging 
TLV (mL) 5512 (4445;6579) 6697 (4605;8788)
hTLV (mL/m) 3207 (2627;3786) 3940 (2722;5157)
TKV (mL)b 1543 (319;2768) 1545 (389;2701)
hTKV (mL/m) b 897 (189;1605) 904 (240;1567)
Data are reported as median a [IQR], mean (95% CI) or absolute numbers (%). Abbreviations: ADPKD, 
autosomal dominant polycystic kidney disease; ADPLD autosomal dominant polycystic liver disease, BMI, 
body mass index; hTKV, height adjusted total kidney volume; hTLV, height adjusted total liver volume; TKV, 
total kidney volume; TLV, total liver volume; UDCA, ursodeoxycholic acid. bADPKD patients only. 
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Liver cyst volume
Mean LCV increased 376 ml (95% CI: 131-620 ml) in the control group compared to 342 ml 
(95% CI: 63-621 ml) in the UDCA group (p = 0.848) (Table 2). Notably, sub-group analysis in 
ADPKD patients disclosed a significantly higher increase in LCV in the control group (470 ml, 
95%CI: 100;840 ml) compared to the UDCA group (81 ml, 95%CI: -103;264 ml) (p = 0.049). In 
contrast, in ADPLD patients there were no differences in LCV change between the UDCA and 
control group detected (473 ml, 95%CI: 63;882ml vs. 202 ml, 95% CI:-56;461ml, p = 0.296).
Kidney volume 
Proportional change in TKV of ADPKD patients (n=16) from baseline to week 24 was not 
different between the UDCA and control group (0.5% vs. 0.6%, p = 0.858). Interestingly, hTKV 
increased significantly from 897 ml/m (95% CI: 189-1605) to 917 ml/m (95%CI: 199-1635) 
in the control group (p = 0.044) but not in the UDCA group (904 ml/m to 913 ml/m, p = 0.213). 
Though, analysis between groups showed no statistical significant change (p=0.335) (Table 2).
Symptoms and quality of life
EORTC score improved by 6 points in UDCA treated patients and worsened by 4 points in 
control group patients (p=0.039) (Supplementary Table 1). In a subgroup analysis of UDCA 
treated ADPLD patients, EORTC score improved by a mean decrease of 10 points (95% CI: 
-20;0, p = 0.047) while score increased with 2 points in the control group (95% CI: -7;11, p = 
0.628). This improvement in the UDCA group tended to be larger than in the control group (p 
= 0.064).
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Figure 4. Individual TLV changes in the control and UDCA group after 24 weeks. A total of 28 patients 
show an increase in TLV, while TLV decreases in 6 patients, 3 in the control and 3 in the UDCA group.
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No significant symptom improvement was seen in PLD-Q and GI-Q symptom scores (respec-
tively, -3 vs. -7 p = 0.306 and -0.1 vs -0.3, p = 0.419). Quality of life as measured by PCS 
and MCS score of SF-36 and VAS-EQ5D were not different from baseline to week 24 between 
control and UDCA group (respectively, p = 0.505, p = 0.819 and p = 0.255). 
 
Safety endpoints: serum liver tests
No changes in biochemical tests were observed from baseline to week 24 between treatment 
arms, except for GGT (Supplementary Table 2). GGT significantly decreased in the UDCA group 
from 2.45 times upper limit of normal (ULN) (IQR: 1.18-4.71 times ULN) to 0.75 times ULN (IQR: 
0.49-1.00 times ULN) and increased in the control group from 1.58 times ULN (IQR: 1.00-3.15 
times ULN) to 1.85 (IQR: 0.97-3.49 times ULN) times ULN (p<0.001 between treatment groups). 
In addition, AP decreased in the UDCA group (p = 0.017) but not in the control group (p = 
0.277). Though, change in AP was not statistically different between groups (p = 0.086). 
Adverse events
Three patients were hospitalized during the trial: one patient (UDCA group) because of a 
brain contusion after falling down the stairs, one patient (control group) suffered from severe 
abdominal pain suspected for a liver or kidney cyst rupture, and one patient (control group) 
because of a shoulder injury. In addition, one patient (control group) was diagnosed with breast 
cancer during the trial. There were no serious adverse events related to the study drug. 
A total of 15 (94%) participants in the UDCA group and 12 (71%) in the control group had 
at least one adverse event (p=0.085) (Supplementary Table 3). Most common adverse events 
in the UDCA group compared to the control group were frequent stools or diarrhea (38% vs. 
12%, p = 0.017) probably related to the study drug.
DISCUSSION
The objective of this study was to evaluate the efficacy and safety of UDCA in patients with 
advanced PLD with an underlying disease of ADPKD or ADPLD. Our results indicate that UDCA 
treatment for 24 weeks did not reduce TLV in patients with advanced PLD. Proportional liver 
volume, hTLV and absolute liver volume were unaffected by UDCA in the whole treatment 
group and remained within margins seen in controls. However, post-hoc analysis revealed 
beneficial effect of UDCA on LCV growth in ADPKD compared to ADPLD. Therefore, the effect of 
UDCA on liver disease in ADPKD need further exploration. 
Our main findings of the effect of UDCA on TLV in PLD are in line with results from an un-
controlled pilot study that reported on a 1-year UDCA treatment of 7 PLD patients. 29 The 
re sults of this study showed no statistically significant difference between liver growth one 
year before treatment and one year after treatment, but indicated a tendency of liver growth 
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inhibition in the UDCA group. However, results need to be interpreted with caution as the 
sample size was small, no control group was included, and a very low dose of UDCA (300mg/
day) was applied. 29 
The main question that needs to be discussed is why UDCA failed to reduce TLV in our study 
population. Our hypothesis that UDCA reduces TLV in advanced PLD was based on experiments 
in PCK rats, an animal model of PLD 11, 17, and on former studies on signaling properties of UDCA 
conjugates in hepatocytes and cholangiocytes 30. It might be that PCK rats do not recapitulate the 
whole spectrum of molecular events leading to PLD in humans and that, at best, experimental 
observations from PCK rats can only be translated to the molecular pathophysiology of some 
PLD subgroups. Thus, it remains unclear whether the PLD patient population selected for this 
trial was the adequate target population for UDCA treatment in PLD. 
Secondly, it can be debated whether PLD stage in our study population can be compared to 
that of the PLD stage studied in PCK rats. PCK rats received UDCA for 5 months starting at an 
age of 8 weeks, when the disease is mild and in progression. 17, 31 In contrast, UDCA therapy was 
here initiated in patients with advanced PLD and who were diagnosed with PLD for a mean of 
11 ± 6 years. In addition, PCK rats have a life span of 1.5 years and received UDCA for 5 months 
while our study population received UDCA for 6 months on a much longer life span. One could 
speculate that earlier and more sustained intervention with UDCA might be more effective 
than a short-term intervention at an advanced stage of PLD.17
A third explanation might be that the effect of UDCA is smaller than the effect size we powered 
on. The a priori calculated number of patients needed for our study was based on the power 
to detect a clinical difference of at least 4% of TLV over 6 months, but not LCV as tested in 
PCK rats. This effect size was based on former studies with somatostatin analogues. 28 It is 
possible that UDCA affects liver volume in PLD, but the short-term effect would be smaller than 
that seen with a 6 month-course of somatostatin analogues. 6-8 In addition, it remains unclear 
whether longer UDCA treatment (2-4 years) in ADPKD could be more effective than long-term 
somatostatin treatment considering that LCV was reduced in ADPKD after 6 months in our 
study.
Interestingly, our results showed a significant improvement in HRQL after UDCA treatment, 
as measured by EORTC questionnaire, while scores on other HRQL symptom questionnaires 
remained unchanged. As change in TLV after 24 weeks of UDCA treatment did not differ 
compared to change of TLV in the control group, chance or a placebo effect might be the root 
cause for the improvement in HRQL.
This brings us to the first limitation of our trial: the lack of double-blinding for treatment allo-
cation. However, the primary outcome change in TLV, was analyzed in a blinded objective 
fashion. Therefore, we assume that the absence of blind patients and physicians did not affect 
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
114
Chapter 6b
our primary outcome. However, it could affect secondary outcomes such as HRQL and symptom 
burden. Secondly, our study was not powered for subgroup analyses of ADPKD and ADPLD 
patients. Thus, subgroup analyses were explorative by nature. The positive effects of UDCA 
treatment on LCV in the subgroup of patients with ADPKD, although borderline significant, are 
intriguing and might be studied in the future.
The international multicenter design of our trial was our key strength as it increases the gene-
ralizability of our findings. Another absolute strength of our trial is that we included a control 
group and were able to compare the effect of UDCA to standard of care.
In conclusion, UDCA administration showed no benefit in reducing TLV in advanced symptomatic 
PLD patients but decreased LCV in ADPKD patients. Further exploration of differences between 
ADPKD and ADPLD patients in the treatment response to UDCA, minimum duration and dose of 
UDCA treatment, appear warranted. Future studies should also focus on unraveling additional 
molecular targets involved in cystogenesis of different forms of PLD.
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SUPPLEMENTARY FILES
Supplementary File 1. Inclusion and exclusion criteria
Inclusion criteria
• 18 ≤ age ≤ 80 years
• PLD, defined as > 20 liver cysts on CT or MRI scan, with underlying diagnosis of ADPLD 
or ADPKD
• TLV ≥ 2500 mL
• Symptomatic defined as ECOG ≥ 1 (31), and having at least three out of ten PLD 
symptoms
• Signed informed consent
Exclusion criteria
The following exclusion criteria will be assessed by questioning the patient and assessing 
patient his medical file.
• Use of oral contraceptives or estrogen supplementation
• Use of UDCA within three months prior to baseline
• Females who are pregnant or breast-feeding or patients of reproductive potential not 
employing an effective method of birth control.
• Intervention (aspiration or surgical intervention) within six months before baseline
• Treatment with somatostatin analogues within six months before baseline
• Renal dysfunction (estimated glomerular filtration rate calculated by the
• Modification of Diet in Renal Diseases (MDRD) < 30 ml/min/1.73m2)
• Patients with a kidney transplant
• Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase 
deficiency or glucose-galactose malabsorption
• Acute cholecystitis or frequent biliary colic attacks
• Acute stomach or duodenal ulcers
• Inflammation of small intestine or colon
• Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide 
or cyclosporine 
• Enrolment in another clinical trial of an investigational agent while participating in this 
study
The following exclusion criteria will be judged by the investigator screening the patient for 
eligibility:
• History or other evidence of severe illness or any other conditions which would make 
the patient, in the opinion of the investigator, unsuitable for the study
• Mental illness that interferes with the patient ability to comply with the protocol
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Ursodeoxycholic acid in polycystic liver disease
6b
Supplementary Table 3. Number of episodes of adverse events
Adverse event
Control group n (%)a
n=17
UDCA group n (%)
a n=16 p value
Digestive tract
Frequent stools/diarrhea 2 (12) 8 (38) b 0.017
Sticky tools 0 (0) 3 (19) 0.061
Bloating belly/abdominal tension 2 (12) 3 (19) 0.576
Stomach cramps 0 (0) 2 (13) 0.133
Flatulence 0 (0) 1 (6) 0.295
Other
Flue 3 (18) 4 (25) 0.606
Suspicion of cyst rupture (liver/kidney) c 1 (6) 3 (13) b 0.258 
Pneumoniae 2 (12) 1 (6) 0.582
Breast carcinoma c 1 (6) 0 (0) 0.325
Brain contusion c 0 (0) 1 (6) 0.485
Crushed shoulder c 1 (6) 0 (0) 0.325
Dose reductions NA 0 (0) -
Drug discontinuation NA 0 (0) -
a Denominator is total of patients in study arm.
Abbreviations: NA, not applicable.
b More than 1 episode of adverse event in 1 patient.
c Serious adverse events
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Chapter 7
GENERAL DISCUSSION
The aim of this thesis was threefold,
1. to assess the role of kidney and liver volume in symptom burden in autosomal dominant 
polycystic kidney disease (ADPKD) patients;
2. to characterise the population of PLD patients who were in need of therapy and explore 
factors involved in treatment decisions;
3. to test ursodeoxycholic acid (UDCA) in PLD.
Following these aims, our research questions were as follows;
1. Who should we treat and what should we target?
2. Who do we treat?
3. A novel therapy for PLD?
Answers to the research questions and implications
1. Who should we treat and what should we target?
Our national cohort study included data on kidney volume, liver volume and symptom burden 
of 309 ADPKD patients. We demonstrated that combined kidney and liver volume (hTKLV) in 
ADPKD was associated with the presence and severity of pain and gastrointestinal symptoms, 
though correlations were weak. Liver volume (hTLV) determines symptoms, in contrast to 
kidney volume (hTKV) which is not associated with symptom burden. 
These results are in line with a large cohort study in ADPKD patients that demonstrated 
a weak association between liver volume and the domain “physical functioning” of the SF-
36. 1 A cohort study in 92 PLD patients, found no association between liver volume and the 
physical component score of the SF-36. The physical component score summarizes physical 
quality of life based on several domains. 2 This study selected patients from two trials that 
included mainly severe PLD patients who were often symptomatic and had large liver volumes. 
3, 4 We think that the large range in liver volumes and symptoms in our cohort contributed to a 
positive relation between liver volume and symptom burden. 2 The difference in results might 
also be due to the type of questionnaire. We specifically assessed gastrointestinal symptoms, 
while former studies used the SF-36, a general questionnaire to measure quality of life. This 
complicates comparison of results. It is my recommendation to systematically assess PLD 
symptoms in ADPKD patients via a validated questionnaire developed for PLD, the PLD-Q. 5
The weak association of liver volume with symptoms implies that other factors contribute 
to symptom burden as well. In our cohort, a history of liver pain, renal pain, urinary tract 
infection, liver cyst infection, renal cyst infection, macroscopic hematuria and renal surgery 
were significantly associated with symptom burden. However, these are factors that cannot be 
targeted in clinical practice and we should examine whether factors such as coping, that can be 
targeted, play a role in symptom burden.
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The association of volumes with symptoms was analyzed in a cross-sectional fashion. Therefore, 
we were not able to evaluate the impact of reduction of total kidney liver volume on symptom 
burden. Our data were extracted from the DIPAK-1 study, an ongoing prospective randomized 
clinical trial assessing the efficacy of lanreotide on renal function decline, kidney volume and 
liver volume, in a large group of ADPKD patients. Longitudinal results will follow in the near 
future, but the weak association between hTKLV and symptoms might implicate that reduction 
in volume will not improve symptom burden. 6
Our data show that symptoms were more prevalent in women than men. This gender specificity 
is in line with results from previous studies. 1, 7 The burden of symptoms in women can be 
explained by larger liver volumes, a well-known phenomenon in women, most likely a conse-
quence of estrogen levels. 8
The results of our cross-sectional analysis have several implications. First, our results suggest 
that we need to target the liver in order to affect symptom burden, especially in women who 
are more at risk to be symptomatic. Secondly, we need to establish whether other factors 
contribute to symptom burden and can be a target for therapy. Finally, as liver volume plays a 
major role in presence and severity of pain and gastrointestinal symptoms, imaging of the liver 
should be part of the initial assessment of all ADPKD patients, as already been recommended 
in the Kidney Disease: Improving Global Outcomes guidelines. 9 This will help to diagnose PLD 
in early disease stages and to intervene appropriately. 
2. Who do we treat?
The results of our cohort study indicate that the liver should be the main target for therapy. 
Unfortunately, current therapies that reduce liver volume in PLD are invasive and have high 
complication and recurrence rates 7, and there are no clear guidelines on treatment of PLD. 
This might explain the results of our international registry that show a large variation in the 
decision to treat and treatment strategies, among two European tertiary referral centers for 
PLD. Our results demonstrated that the choice for a specific therapy such as fenestration or 
aspiration sclerotherapy is center-dependent. Patients who underwent fenestration or aspira-
tion sclerotherapy had comparable patients ‘characteristics without differences in pheno type. 
This could implicate that expertise drives treatment and that evidence supporting the efficacy 
of therapies is lacking. 
Presence of symptoms and every 10 years of PLD diagnosis increased the likelihood to 
undergo treatment by 40%. Our data should be interpreted with caution as symptom burden 
was not systematically assessed through a validated questionnaire. Center played a significant 
role in the choice for either liver transplantation or aspiration sclerotherapy. This underscores 
that available expertise drives treatment while evidence that singles out the best treatment 
modality is lacking. 
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A high number of patients received multiple treatment strategies (14%). Results from a retro-
spective cohort study including ADPLD patients showed that 56% of the treated population 
received more than one treatment strategy. 10 Both results might suggest that current therapies 
are not effective in reducing symptoms, which is at odds with literature on the efficacy of 
invasive therapies for PLD. 11-14 Recurrence might be another explanation why patients received 
multiple treatment strategies.
Liver volume was not available in medical records of most cases included in our registry and 
we were not able to investigate the role of liver volume on treatment decision or strategy. The 
lack of liver volumes in medical records could indicate that liver volume assessment is not part 
of clinical routine or does not play a major role in treatment decision. It might also indicate that 
routine measurement is not possible due to a lack of equipment or time, as volumetry is time-
consuming (45-60 minutes per scan). 
In conclusion, a higher number of symptoms and every 10 years of PLD diagnosis increases the 
likelihood to undergo treatment. Center plays a major role in the choice to elect a particular 
modality. The absence of the systematically collection of data on symptom burden and liver 
volume made it impossible to assess efficacy of treatment. Therefore we recommend to assess 
symptom burden by the PLD-Q, 5 and liver volume by volumetry, both pre- and post therapy to 
evaluate the efficacy of current treatment strategies.
3. A novel therapy for PLD?
According to the results of our registry, a large group of patients in tertiary centers receives 
invasive therapy (35%). Patients are mostly referred to tertiary centers because of symptomatic 
PLD. Therefore it might be that even a larger group of patients is in need of therapy but does not 
fulfil the criteria for current strategies, or is unwilling to receive invasive therapy. Clearly there 
is a need for a non-invasive therapy. Previous studies exploring the mechanism of cystogenesis 
in PLD demonstrated that cholangiocytes from PCK rats, an animal model that resembles 
human PLD, have increased intracellular cAMP levels and diminished Ca2+ levels compared 
to normal human cholangiocytes. Restoration of these levels mediated hyperproliferation in 
cholangiocytes of PCK rats. 15 UDCA restored diminished Ca2+ levels and decreased hepatic 
cystogenesis in PCK rats after five months of treatment. 16, 17 We designed an international, 
multicenter, randomized controlled phase 2 trial to assess the efficacy of UDCA in advanced 
PLD patients. 
Our results demonstrate that UDCA treatment for 24 weeks does not reduce total liver volume 
in patients with advanced PLD. These results are in line with another trial that investigated 
the effect of UDCA on liver volume. 18 This observational trial demonstrated that there was no 
statistically significant difference between liver growth one year before and after treatment 
with UDCA. A limitation is that no control group was included and that a very low dose of 
UDCA was used. The question is why UDCA failed to reduce total liver volume (TLV) in PLD 
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patients? One of the explanations might be that the data from the PCK rat model cannot be 
extrapolated (where somatostatin analogues work 3, 19) to the situation in humans. Another 
explanation might be the choice of our study population. We tested UDCA in advanced human 
PLD, while the PCK rats used in the experiments were only eight weeks old. As a results, UDCA 
might be effective in early stages of the disease instead of advanced disease. Moreover, PCK 
rats live about 1.5 years and they received UDCA for five months, while our patients received 
UDCA for six months but have a much longer life span. This would indicate that we should treat 
patients for a longer period to achieve a similar effect.
In a post-hoc subgroup analysis, we were able to detect a significant smaller liver cyst growth 
rate in ADPKD patients treated with UDCA, compared to ADPKD control patients. This effect was 
not seen in ADPLD. However, results should be interpreted with caution as our sample size was 
not powered on the effect of total cyst volume.
Our results suggest that there is no role for UDCA in the treatment of PLD, at this moment. 
The results of our post-hoc subgroup analysis suggest that there might be differences in the 
molecular mechanisms of cystogenesis in ADPKD and ADPLD patients, that need different 
therapeutic approaches. 
Limitations and strengths
In order to study the association of liver and/or kidney volume with symptom burden in ADPKD 
patients, we used a cross-sectional analysis. The main strength of this cross-sectional analysis 
was the use of baseline characteristics of a prospective protocolized trial which prevented 
missing data. The limitation of a cross-sectional analysis is that no conclusions can be drawn 
about longitudinal effects such as the role of liver growth in symptom burden. For the timing of 
treatment, this information is important. However, as our data were extracted from an ongoing 
prospective randomized clinical trial6, these results will be available in the near future. 
Our PLD registry is a robust method to systematically collect data on factors involved in 
treatment decision in PLD. The international ground had several advantages. First, it facilitated 
the inclusion of a large group of patients with a rare disease such as PLD. Second, we could 
study the effect of center on treatment decision. Third, in the future it will help to select patients 
for clinical trials. The retrospective character of our data analysis hurdles the exploration of the 
whole spectrum of factors that might be involved in treatment decision. We were dependent on 
the information in medical records of patients, which were often incomplete. Our international 
PLD registry will therefore continue as a prospective database including longitudinal data on 
liver growth and symptom burden.
A randomized controlled trial was the best method to test whether UDCA is an effective 
therapy for PLD. The rarity of PLD makes it a challenge to achieve the desired inclusion, but 
the international character of our trial helped. Ideally, a placebo controlled trial is preferable, 
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though this is very expensive and since TLV is an objective endpoint a placebo group would 
probably have not changed the results.
Future perspectives
Future research should focus on the following topics.
1. The effect of liver volume reduction on symptom burden
Liver volume plays a role in symptom burden in ADPKD patients, while kidney volume does 
not. The next step is to assess the effect of liver volume reduction on symptom burden. The 
result of the DIPAK-1 study should therefore be awaited.6 
2. Other determinants for symptom burden
The weak association between liver volume and symptom burden in our cohort of ADPKD 
patients suggests that other factors play a role as well. Identification of these elements help 
to design better targeted interventions and to tailor therapy according to the proportional 
reduction of liver volume. 
3. Defining an endpoint
Our PLD registry indicates that there is a lack of evidence on efficacy of therapies for PLD. 
To evaluate efficacy of therapies through a clinical trial we need well defined endpoints. The 
most desired outcome of an intervention in PLD is reduction of symptoms, though PLD is 
often associated with non-specific symptoms. A composite endpoint including liver volume 
and symptom burden, might be desirable. For symptom burden, a validated PLD specific 
questionnaire such as the PLD-Q can be used. 5 In order to collect data on liver volume, there is 
a need for a quick and accurate method to measure liver volume independent of time and place 
and within a reasonable time frame. Combining a PLD-Q score reduction with liver volume or 
growth reduction, might be an excellent composite endpoint for assessment of efficacy of PLD 
therapies.
4. Efficacy of current therapies
The results of our registry indicated that the choice for aspiration sclerotherapy or fenestration 
is center-dependent. A randomized trial to compare the efficacy of both therapies should be 
performed to elucidate the best therapy is. In addition, physicians in clinical practice could 
eval uate short- and long-term efficacy of current therapies by assessing liver volume and 
symptom burden pre- and post treatment. This will help to build an evidence base for current 
therapies.
5. Design a non-invasive therapy
There is definitely a need for a non-invasive therapy for PLD. Future studies should focus 
on testing drugs that alter mechanism involved in cystogenesis, such as the cAMP mediated 
hyper proliferation of cystic cholangiocytes, in order to change natural course of PLD. 
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For UDCA, ongoing research is needed to find out whether longer treatment with UDCA or a 
higher dose might be effective in PLD. As UDCA might have different effects on cyst volume in 
ADPKD and ADPLD patients, it might be worth considering to assess disease specific differences.
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ENGLISH SUMMARY
Polycystic liver disease (PLD) is characterized by the development of multiple cysts spread 
throughout the liver. PLD is present in two genetically distinct disorders, as a primary phenotype 
in autosomal dominant polycystic liver disease (ADPLD) and secondary to renal cysts in 
autosomal dominant polycystic kidney disease (ADPKD). The natural course of PLD shows a 
progressive increase in number and size of hepatic cysts. This can result in hepatomegaly. A 
normal liver weighs about 1.5L. In patients with severe PLD the liver can grow up to 5-10 times 
its normal size, although liver function remains intact. As a consequence of progressive cyst 
growth, patients can develop symptoms such as abdominal pain, early satiety and dyspnea. 
For patients with symptomatic PLD several treatment options are available. Aspiration sclero-
therapy is indicated in patients with a dominant cyst that is clearly responsible for the 
symptoms. The procedure involves radiological aspiration of cyst fluid and subsequent admini-
stration of a sclerosing agent to destruct the cyst wall. Surgical treatment options are fene-
stration, resection or liver transplantation. Fenestration involves surgical deroofing of cysts and 
is indicated in patients with multiple superficial large cysts. Resection means that a segment of 
the liver will be removed. This is indicated in patients who have a phenotype with at least one 
segment of unaffected liver parenchyma. Above mentioned therapies are invasive and have a 
high risk of complications and recurrence. A liver transplantation is the only curative treatment, 
however this is an invasive procedure and due to scarcity of donors not widely performed in 
patients with PLD. 
Because all available treatment options are invasive, we need to preserve them for those 
patients that are symptomatic or have a high likelihood to develop symptoms. However, at this 
moment we are not yet able to predict who will develop symptomatic PLD. Besides, the relation 
between liver volume and symptom burden is not entirely clear. There are no guidelines to 
initiate therapy in PLD and we do not know which factors play a role in initiating therapy, and 
the choice for a specific treatment strategy. Finally, there is a need for a non-invasive therapy 
that alters natural course in order to reduce or prevent symptoms. This thesis addresses several 
of these issues. 
Former research has shown that there are several risk factors for developing symptomatic PLD. 
In my thesis, we gave an overview of these risk factors (chapter 2). 
It seems logical that an increase in liver volume is associated with symptoms. Though, evidence 
is inconclusive. In this thesis we have studied the relation of combined liver and kidney volume 
with symptoms (chapter 3). We explored this relation in a population of ADPKD patients, as 
PLD is mainly present in this disorder. Results showed that a combination of kidney and liver 
volume is associated with symptom burden with a prominent role for liver volume. There was 
Processed on: 13-1-2017
507398-L-sub01-bw-Hedwig
137
English summary
no association between kidney volume and symptoms. These findings implicate that physicians 
should target liver volume to reduce symptoms in ADPKD patients.
However, there are no guidelines that help physicians to choose a specific treatment for 
patients with PLD. To find out which factors play a role in the initiation of therapy and the 
choice for specific treatment strategies, we created an international registry. First, we explored 
the litera ture to find the elements needed for a successful database (chapter 4). The results of 
our international registry showed that 35% of patients from one of both nationwide tertiary 
centers, received invasive treatment (chapter 5). The likelihood to receive treatment increased 
with number of symptoms and with the number of years the diagnosis of PLD was present. 
The choice for either liver transplantation or aspiration sclerotherapy was center-dependent. 
Differences in treatment decisions between both centers implicated that there is a lack of 
evidence on the best treatment strategy for PLD. 
As current therapies are invasive and have high complication risks and recurrence rates, we 
developed an international trial to assess the efficacy of ursodeoxycholic acid (UDCA) to 
reduce liver volume in PLD (chapter 6a). In total we included 34 patients with symptomatic 
hepato megaly. Patient were randomized to receive either UDCA or no treatment for 24 weeks. 
Results showed that UDCA was not effective in reducing liver volume (chapter 6b). A post-hoc 
subgroup analyses revealed that liver cyst growth was less in UDCA-treated ADPKD patients 
versus ADPKD patients who received no treatment. This result was not shown in ADPLD 
patients. At this moment there is no role for UDCA in the treatment of PLD. Future research 
needs to find out whether ADPKD and ADPLD patients respond differently to UDCA.
The results of my thesis showed that liver volume plays a role in symptomatic ADPKD and that 
treatment should target the liver in order to reduce symptom burden. Current therapies that 
target liver volume however, are very invasive and center seemed to play an important role 
in the treatment decision and the strategy chosen. Therefore, future studies are needed to 
investigate the efficacy of current therapies. UDCA as a non-invasive therapy for PLD has no 
role in the treatment of symptomatic PLD at this moment. 
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Polycysteuze leverziekte (PLD) kenmerkt zich door de ontwikkeling van multipele cysten ver-
spreid door de lever. PLD komt voor bij twee genetische aandoeningen: in combinatie met 
cystenieren bij autosomaal dominante polycysteuze nierziekte (ADPKD) en geïsoleerd in 
de lever bij autosomaal dominant polycysteuze leverziekte. Het natuurlijke beloop van PLD 
karakteriseert zich door een progressieve toename in aantal en grootte van levercysten. Dit 
kan resulteren in hepatomegalie. Een lever weegt normaliter zo’n 1.5 liter. Bij patiënten met 
ernstige PLD kan de lever wel 5-10 keer zo groot worden. Deze patiënten kunnen dan klachten 
ontwikkelen zoals buikpijn, snel een vol gevoel  na het eten en kortademigheid. De leverfunctie 
in patiënten met PLD blijft intact. 
Voor patiënten met symptomatische PLD bestaan er verschillende behandelingsmogelijkheden. 
Aspiratie sclerotherapie is een behandeling waarbij een symptomatische dominante cyste 
leeg wordt gezogen en alcohol wordt ingespoten om te zorgen dat de cyste verdwijnt. De chi-
rurgische opties zijn fenestratie, resectie of levertransplantatie. Fenestratie kan worden uit-
gevoerd wanneer patiënten meerdere grote cysten hebben. De cysten worden dan operatief 
verwijderd. Bij een leverresectie wordt een deel van de lever verwijderd. Dit kan alleen wanneer 
de cysten zich met name in één deel van de lever bevinden en er voldoende leverweefsel 
zonder cysten overblijft. Bovenstaande therapieën zijn invasief en hebben een hoog risico 
op complicaties en recidieven. Een levertransplantatie is de enige genezende behandeling. 
Doordat ook dit een invasieve procedure is en donoren schaars zijn, wordt deze therapie 
weinig toegepast bij patiënten met PLD.
Omdat de huidige therapieën invasief zijn worden deze met name toegepast bij symptomatische 
patiënten of in patiënten die een grote kans hebben op het ontwikkelen van klachten. Op dit 
moment zijn we niet in staat te voorspellen welke patiënten symptomatische PLD ontwikkelen. 
Daarnaast is de relatie tussen het volume van de lever en symptomen niet geheel duidelijk. 
Tevens zijn er geen richtlijnen voor het starten van therapie. De vraag is dan ook welke fac-
toren een rol spelen bij het initiëren van behandeling en de specifieke keuze voor een van 
de bovengenoemde behandelingsstrategieën. Tenslotte is er behoefte aan een niet-invasieve 
behandeling die het natuurlijk beloop van PLD kan beïnvloeden en klachten kan verminderen 
of voorkomen. In deze thesis worden verschillende van deze vraagstukken besproken.
Voorgaand onderzoek heeft laten zien dat er verschillende risicofactoren zijn voor het 
ontwikkelen van symptomatische PLD. In mijn proefschrift heb ik een overzicht gegeven van 
deze risicofactoren (hoofdstuk 2). 
Logischerwijs denkt men dat levergrootte in verband staat met de klachten die patiënten 
ervaren. Echter, het bewijs hiervoor is niet eenduidig. Ook de rol van cystenieren hierin is 
onduidelijk. In dit proefschrift hebben we het onderzoek beschreven de relatie tussen het 
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gecombineerde lever- en niervolume, en symptomen onderzocht (hoofdstuk 3). We hebben 
dit onderzoek uitgevoerd bij patiënten met ADPKD omdat dit de grootste groep patiënten is 
waarbij PLD voorkomt. De resultaten lieten zien dat de combinatie van lever- en niervolume 
geassocieerd is met zowel gastrointestinale klachten, als pijn. Dit was met name te wijten aan 
het levervolume en er was geen aantoonbare relatie tussen niervolume en klachten. Deze 
bevindingen impliceren dat artsen bij patiënten met symptomatische ADPKD een behandeling 
moeten inzetten die zich richt op het reduceren van het levervolume.
Helaas bestaat er geen richtlijn die artsen helpt bij de keuze van een behandeling voor pa-
tiënten met PLD. Om te onderzoeken welke factoren een rol spelen bij het starten van 
behandeling en de keuze voor een specifieke behandelingsstrategie, hebben we een inter-
nationale database opgezet. Allereerst hebben we literatuuronderzoek gedaan om na te gaan 
aan welke eigenschappen een succesvolle database moet voldoen (hoofdstuk 4). Het onder-
zoek in de populatie opgenomen in mijn internationale database liet zien dat 35% van de 
patiënten afkomstige uit twee nationale tertiaire centra, worden behandeld met invasieve 
therapie (hoofdstuk 5). Het wel of niet ondergaan van een behandeling is onder andere 
afhankelijk van het centrum waar de patiënt terecht komt. De kans op behandeling neemt toe 
met het aantal symptomen en naarmate men langer de diagnose PLD heeft. Het verschil in 
behandeling tussen beide centra suggereert dat bewijs ontbreekt wat de beste behandeling is 
van een patiënt met PLD.
Aangezien de huidige behandelingen invasief zijn hebben we een internationale studie op gezet 
om na te gaan of ursodeoxycholzuur (ursochol) in staat was om het levervolume te redu ceren 
in patiënten met PLD (hoofdstuk 6a). We hebben in totaal 34 patiënten met sympto matische 
hepatomegalie in deze studie geïncludeerd. De helft van deze patiënten werd behandeld met 
ursochol gedurende 24 weken en de andere helft kreeg geen behandeling. De resultaten van 
deze studie laten zien dat ursochol niet effectief was in het verkleinen van het levervolume 
(hoofdstuk 6b). Een subgroepanalyse in patiënten met ADPKD liet zien dat de levercysten bij 
hen minder hard groeiden in vergelijking met de levercysten in patiënten met ADPKD niet 
behandeld werden. Dit resultaat was niet zichtbaar in ADPLD patiënten. Op dit moment lijkt 
ursochol geen effectieve therapie voor het verkleinen van het levervolume in patiënten met 
PLD. Verder onderzoek moet uitwijzen of ADPKD en ADPLD patiënten verschillend reageren 
op ursochol.
De resultaten van mijn thesis laten zien dat levervolume een rol speelt in symptomatische 
ADPKD patiënten en dat behandeling gericht moet zijn op de lever. Huidige therapieën die 
het levervolume beïnvloeden zijn erg invasief en het behandelcentrum speelt een belangrijke 
rol in de keuze voor een specifieke behandelingsstrategie. Een niet-invasieve behandeling 
middels ursochol lijkt op dit moment niet effectief voor de behandeling van patiënten met 
symptomatische PLD. 
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DANKWOORD 
Beste Professor Drenth, beste Joost, door dit promotietraject heb jij me de kans gegeven om 
me op zowel wetenschappelijk als persoonlijk gebied te ontwikkelen. Bedankt voor de vele 
inzichten die je mij hebt gegeven. Ik heb bewondering voor jouw organisatievaardigheden 
want ondanks een overvolle agenda had je altijd tijd en ruimte voor een kritische blik.
De leden van de manuscriptcomissie, Prof. dr. Hilbrands, Prof. dr. Janssen en Prof.dr. Westert, 
hartelijk dank voor het grondig doornemen van mijn proefschrift.
Lieve papa, mama, zus, zwager & mijn allerliefste nichtje. Afgelopen jaren zijn met jullie steun 
en toeverlaat een groot succes geworden. Ik heb het enorm getroffen met zo’n lieve familie die 
altijd voor mij klaarstaat! Trots en blij ben ik dat jullie getuigen zijn van mijn promotie.
Mijn allerliefste Thomas, wat ben ik ontzettend blij dat ik jou heb leren kennen. Bij de laatste 
meters van dit proefschrift was jij mijn rots in de branding.  Ik hoor het je nog zeggen, je weet 
het, “de laatste loodjes wegen het zwaarst”. Ik ben enorm gelukkig met jou en ik hoop dat dit 
eeuwig duurt! Bedankt dat je er altijd voor me bent.
In 2004 ging ik studeren in het zuiden des Lands, Maastricht wel te verstaan. Gedurende het 
introductiekamp van gezondheidswetenschappen heb ik daar met een aantal studenten een 
spel mogen ontdekken, genaamd “stuiteren”. U kent het wellicht niet, maar het spel stuiteren is 
een combinatie van volleybal en voetbal. Helaas voor ons is het stuiteren nog geen Olympische 
sport, maar een clublied hebben we al wel. Tijdens het stuiteren is de basis gelegd voor een 
hechte vriendengroep, onder de naam, u raadt het al “de Stuiters”. Deze groep, bestaande uit 
3 vrouwen en 4 mannen bevat mensen met passie, diepgang, humor en veel liefde. Met trots 
kan ik u vertellen dat ik daar deel van mag uitmaken. Ondanks dat we elkaar niet meer zo vaak 
zien als vroeger zorgt een avond of weekend met jullie altijd voor geweldige momenten en 
memorabele herinneringen. Lieve Stuiters, ik wil jullie bedanken voor onze vriendschap!  
Eén jaar na het begin van mijn studie gezondheidswetenschappen ben ik lid geworden van het 
onafhankelijke dames dispuut Bon’Aparte. Hier heeft zich in het jaar 2005 te Maastricht een 
prachtige lichting gevormd. Wie had ooit gedacht, dat wij, begonnen als bijtjes, zoveel jaren 
later nog altijd een hechte vriendinnengroep zouden zijn. Lieve meiden, bedankt dat ik altijd 
op jullie kan rekenen.  
Tijdens mijn tweede jaar leerde ik, nota bene tijdens een blok statistiek, Jarinka, Annerika en 
Petra kennen. De meeste studenten werden niet echt enthousiast van dit blok en ik had nooit 
gedacht dat er een tijd zou komen dat ik mij zoveel met statistiek zou bezighouden. Ondanks 
de afstanden tussen onze woonplaatsen maken we geregeld tijd voor een hapje of drankje met 
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elkaar. Lieve meiden, bedankt dat ik altijd mijn successen en teleurstellingen met jullie heb 
kunnen delen! 
Na mijn afstuderen in 2011 ben ik terug gegaan naar mijn roots, het gezellige Brabant. In de stad 
’s-Hertogenbosch ben ik gaan wonen en tevens gaan werken in het Jeroen Bosch Ziekenhuis 
als ANIOS Maag-, Darm- en Leverziekten. Als nieuwe assistent werd ik aan mijn buddy Marjolein 
gekoppeld. Marjolein, internist in opleiding, was een soort van vraagbaak voor mij, zij moest 
mij helpen de weg in het ziekenhuis te leren kennen. Echter, tot op de dag van vandaag moet ik 
de rondleiding in het Jeroen Bosch Ziekenhuis nog steeds krijgen. Dat gemis wordt overigens 
volledig gecompenseerd door onze vriendschap die is ontstaan. We kunnen samen enorm 
lachen en hebben elkaar ook door mindere periodes geholpen. De mooiste herinneringen heb 
ik aan onze reizen door Kenia, Uganda en Guatemala. Ik stel voor dat we in de toekomst nog 
eens zo’n reis gaan maken. Misschien is het dit keer beter met een visum, zodat we wel op de 
vlucht naar Rwanda worden toegelaten.
Tijdens mijn jaar als ANIOS in het Jeroen Bosch Ziekenhuis heb ik een ontzettend fijne tijd 
gehad. Samen met Bianca en Marjolein liepen we als de drie musketiers door het ziekenhuis. 
Zeker ook buiten het werk om hebben we tijdens het hockeyen, wintersport en niet te vergeten 
de vrijdagavondborrels veel lol gehad. Het lijkt me leuk als we in de toekomst nog eens met z’n 
drieën in hetzelfde ziekenhuis komen te werken. Meiden bedankt!
In het jaar 2013 ben ik gestart met mijn promotietraject op de onderzoeksafdeling van de 
Maag-, Darm-, en Leverziekten in het Radboudumc. Veel collega’s hebben mij ondersteund 
gedurende mijn promotietraject. Echter, is er één persoon die ik in het bijzonder wil bedanken. 
Floor, ik denk dat jij wel weet dat ik ontzettend veel aan jou heb gehad tijdens de jaren van mijn 
promotietraject. Soms om te sparren, maar vooral ook om te spuien en wat dieper in te gaan 
op de zaken die onze paden kruisten. Jij hebt me veel geleerd en steun gegeven tijdens onze 
gesprekken, bedankt daarvoor! In de toekomst hoop ik dat we elkaar nog geregeld gaan zien.
Natuurlijk wil ik ook de andere arts-onderzoekers en ex-kamergenootjes bedanken. Dorian, 
Edgar, Isabelle, Jos, Karina, Lauranne, Mark B., Mark. L., Marten, Myrte, René, Simon, Titus, Tom, 
Wybrich, Xavier, Yannick , Yasmijn bedankt voor alle feedback en hulp tijdens mijn promotie-
onderzoek. 
Toen ik in het jaar 2011 verhuisde ben ik gaan hockeyen bij hockeyclub Den Bosch. In het jaar 
2015 ben ik gewisseld van team en bij dames 4 gaan hockeyen. Lieve dames, ik ben ontzettend 
blij dat ik onderdeel ben van dit super leuke team. Door de positieve vibe die altijd binnen het 
team heerst krijg ik enorm veel energie en maakt het mij trots om er deel van uit te maken. 
Naast de fanatieke instelling maken we ook meer dan genoeg tijd vrij voor de 3e helft. Dit 
blijkt vooral tijdens onze aanwezigheid bij de hockeydisco’s en natuurlijk niet te vergeten het 
skiweekend! 
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Er is één persoon die mij naast mijn familie het aller-langste kent en tevens een grote passie 
met mij deelt. Lieve Daan, jaar in jaar uit in hetzelfde hockeyteam met dezelfde spirit om te 
winnen. Ik geniet altijd volop van onze dineravondjes. Bedankt dat jij al zoveel jaren mijn 
vriendin bent!
Beste MDL-collega’s uit ‘s-Hertogenbosch, in oktober 2011 kwam ik vanuit de A-KO opleiding 
bij jullie werken. Wat heb ik dat jaar genoten, ik voelde me als een vis in het water op C6 Zuid 
en ik kreeg de kans van jullie om MDL van A tot Z te ontdekken. Mede dankzij jullie heb ik heb 
veel geleerd en is mijn passie voor MDL dat jaar flink gegroeid, bedankt hiervoor!
In het bijzonder wil ik Loes, mijn zaalsupervisor tijdens mijn ANIOS-schap in ’s-Hertogenbosch 
bedanken. Onze wegen hebben elkaar inmiddels al vaak gekruist. Na mijn zaalsupervisor te 
zijn geweest ging jij naar Nijmegen voor je opleiding en volgde ik. Toen we beide in Nijmegen 
ons promotieonderzoek uitvoerden zijn we zelfs nog een tijd kamergenootjes geweest. 
Vervolgens ben ik jou wederom achterna gereisd naar ‘s-Hertogenbosch. Het is ontzettend 
leuk en fijn om jou als collega te hebben, maar zeker ook buiten het werk heb ik heel veel aan 
onze gesprekken gehad. 
Lieve Chantal, Lauren, Rick, Marja en Loes, jullie hebben in de afgelopen jaren mogen mee-
genieten van de weg die promoveren heet. Bedankt voor jullie steun hierin!
Beste MDL-artsen, AIOS MDL, Jessica, research unit, labafdeling, stafleden, secretaresses en 
Ricky, jullie wil ik bedanken voor de feedback en vragen tijdens de vele presentaties die ik heb 
mogen geven tijdens mijn promotietraject. Mede dankzij jullie heb ik een ontzettend fijne tijd 
gehad in het Radboudumc.
Alle leden van het DIPAK consortium bedankt. Erg blij en trots ben ik dat ik deel heb mogen 
uitmaken van dit inspirerende team. 
Beste dames van de MRI (Manita en Marijke), bedankt voor alle  hulp tijdens de vele onder-
zoeken. Het was fijn om met jullie als team samen te werken!
Graag wil ik alle auteurs bedanken die hebben meegedacht en meegeschreven aan de artikelen 
in dit proefschrift. Jullie feedback en ideeën waren erg waardevol voor het voltooien van dit 
proefschrift. 
Tot slot wil ik graag alle patiënten bedanken die hebben deelgenomen aan de onderzoeken die 
in dit proefschrift zijn verwerkt. Ik heb veel respect en bewondering voor jullie, want zonder 
jullie was dit niet gelukt, bedankt!
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